[21] S.S. Brack, M. Silacci, M. Birchler, D. Neri, Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C, Clin. Cancer Res. 12 (2006) 3208–3208, https://doi.org/10.1158/1078-0432.CCR-05-2804.

[22] K. Tervo, T. Tervo, G. Van Setten, A. Tarkkanen, I. Virtanen, Demonstration of tenascin-like immunoreactivity in rabbit corneal wounds, Acta Ophthalmol. (Copenh.) 67 (1989) 347–350, https://doi.org/10.1111/j.1755-3768.1989.tb01886.x.

[23] E. Balza, A. Siri, M. Ponassi, F. Caocci, A. Linnala, I. Virtanen, L. Zardi, Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin, FEBS Lett. 332 (1993) 39–43, https://doi.org/10.1016/0014-5793(93)80479-E.

[24] S. Schenk, J. Muser, G. Vollmer, R. Chiquet-Ehrmann, Tenascin-C in serum: a questionable tumor marker, Int. J. Cancer 61 (1995) 443–449, https://doi.org/10.1002/ijc.2910610402.

[25] R. Gébleux, M. Stringhini, R. Casanova, A. Soltermann, D. Neri, Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix, Int. J. Cancer 140 (2017) 1670–1679, https://doi.org/10.1002/ijc.30569.

[26] A. Dal Corso, R. Gébleux, P. Murer, A. Soltermann, D. Neri, A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity *in vivo*, J. Controlled Release 264 (2017) 211–218, https://doi.org/10.1016/j.jconcler.2017.08.040.

[27] M.L. Hauck, M.R. Zalutsky, Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: application of the thermal equivalency equation, Int. J. Hyperthermia 21 (2005) 13–27, https://doi.org/10.1080/026567304000011032.

[28] A.T. Yordanov, M. Hens, C. Pegram, D.D. Bigner, M.R. Zalutsky, Antitenascin antibody 81C6 armed with 177Lu: *in vivo* comparison of macrocyclic and acylclic ligands, Nucl. Med. Biol. 34 (2007) 173–183, https://doi.org/10.1016/j.nucmedbio.2006.11.003.

[29] K.S. Midwood, M. Chiquet, R.P. Tucker, G. Orend, Tenascin-C at a glance, J. Cell Sci. (2016), https://doi.org/10.1242/jcs.190546 jcs.190546.

[30] K. Midwood, S. Sacre, A.M. Piccinini, I. Ingis, T. Trebaul, E. Chan, S. Drexler, N. Sofat, M. Kashiwagi, G. Orend, F. Brennan, B. Foxwell, Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease, Nat. Med. 15 (2009) 774–780, https://doi.org/10.1038/nm.1987.

[31] T. Oskarsson, S. Acharyya, X.H.F. Zhang, S. Vanharanta, S.F. Tavazoie, P. G. Morris, R.J. Downey, K. Manova-Todorova, E. Brogi, J. Massagué, Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs, Nat. Med. 17 (2011) 867–874, https://doi.org/10.1038/nm.2379.

[32] C. Spenlé, I. Gasser, F. Saupe, K.P. Janssen, C. Arnold, A. Klein, M. van der Heyden, J. Mutterer, A. Neuville-Méchine, M.P. Chenard, D. Guenet, I. Esposito, J. Slotta-Huspenina, N. Ambartsumian, P. Simon-Assmann, G. Orend, Spatial organization of the tenascin-C microenvironment in experimental and human cancer, Cell Adhes. Migr. 9 (2015) 4–13, https://doi.org/10.1080/19336918.2015.1005452.

[33] H. Tanaka, A. El-Karef, M. Kaito, N. Kinoshita, N. Fujita, S. Horiike, S. Watanabe, T. Yoshida, Y. Adachi, Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C, Liver. Int. 26 (2006) 311–318, https://doi.org/10.1111/j.1478-3231.2005.01229.x.

[34] J. Závada, M. Uher, R. Svobodová, M. Olejárová, M. Hušáková, H. Ciferská, H. Hulejová, M. Tomcík, L. Senolt, J. Vencovský, Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study, Arth. Res. Ther. 17 (2015) 341, https://doi.org/10.1186/s13075-015-0862-4.

[35] D.Aa. Olsen, T. Bechmann, B. Østergaard, P.A. Wamberg, E.H. Jakobsen, I. Brandslund, Increased concentrations of growth factors and activation of the EGFR system in breast cancer, Clin. Chem. Lab. Med. 50 (2012), https://doi.org/10.1515/cclm-2011-0823.

[36] S. Riedl, M. Kadmon, A. Tandara, U. Hinz, P. Möller, C. Herfarth, A. Faissner, Mucosal tenascin C content in inflammatory and neoplastic diseases of the large bowel, Dis. Colon Rectum 41 (1998) 86–92, https://doi.org/10.1007/BF02236901.

[37] E. Ruoslahti, Molecular ZIP codes in targeted drug delivery, Proc. Natl. Acad. Sci. 119 (2022) e2200183119, https://doi.org/10.1073/pnas.2200183119.

[38] K.S. Midwood, T. Hussenet, B. Langlois, G. Orend, Advances in tenascin-C biology, Cell. Mol. Life Sci. 68 (2011) 3175–3199, https://doi.org/10.1007/s00018-011-0783-6.

[39] W. Chen, Y. Wu, J. Wang, W. Yu, X. Shen, K. Zhao, B. Liang, X. Hu, S. Wang, H. Jiang, X. Liu, M. Zhang, X. Xing, C. Wang, D. Xing, Clinical advances in TNC delivery vectors and their conjugate agents, Pharmacol. Ther. 253 (2024) 108577, https://doi.org/10.1016/j.pharmthera.2023.108577.

[40] R.P. Tucker, M. Degen, Revisiting the tenascins: exploitable as cancer targets? Front. Oncol. 12 (2022) 908247 https://doi.org/10.3389/fonc.2022.908247.

[41] M. Chiquet, Tenascin-C: from discovery to structure-function relationships, Front. Immunol. 11 (2020) 611789, https://doi.org/10.3389/fimmu.2020.611789.

[42] P. Murer, D. Neri, Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation, New Biotechnol. 52 (2019) 42–53, https://doi.org/10.1016/j.nbt.2019.04.002.

[43] C. Spenlé, F. Saupe, K. Midwood, H. Burckel, G. Noel, G. Orend, Tenascin-C: exploitation and collateral damage in cancer management, Cell Adhes. Migr. 9 (2015) 141–153, https://doi.org/10.1080/19336918.2014.1000074.

[44] I. Cokgor, G. Akabani, C.T. Kuan, H.S. Friedman, A.H. Friedman, R.E. Coleman, R. E. McLendon, S.H. Bigner, X.G. Zhao, A.M. Garcia-Turner, C.N. Pegram, C. J. Wikstrand, T.D. Shafman, J.E. Herndon, J.M. Provenzale, M.R. Zalutsky, D. D. Bigner, Phase I trial results of iodine-131-labeled antitenascin monoclonal

antibody 81C6 treatment of patients with newly diagnosed malignant gliomas, J. Clin. Oncol. 18 (2000) 3862–3872, https://doi.org/10.1200/JCO.2000.18.22.3862.

[45] C. Grana, M. Chinol, C. Robertson, C. Mazzetta, M. Bartolomei, C. De Cicco, M. Fiorenza, M. Gatti, P. Calici, G. Paganelli, Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: a pilot study, Br. J. Cancer 86 (2002) 207–212, https://doi.org/10.1038/sj.bjc.6600047.

[46] G. Paganelli, M. Bartolomei, M. Ferrari, M. Cremonesi, G. Broggi, G. Maira, C. Sturiale, C. Grana, G. Prisco, M. Gatti, P. Calici, M. Chinol, Pre-targeted locoregional radioimmunotherapy with ⁹⁰Y biotin in glioma patients: phase I study and preliminary therapeutic results, Cancer Biother. Radiopharm. 16 (2001) 227–235, https://doi.org/10.1080/10849780152389410.

[47] D.A. Reardon, M.R. Zalutsky, G. Akabani, R.E. Coleman, A.H. Friedman, J. E. Herndon, R.E. McLendon, C.N. Pegram, J.A. Quinn, J.N. Rich, J. J. Vredenburgh, A. Desjardins, S. Guruangan, S. Boulton, R.H. Raynor, J. M. Dowell, T.Z. Wong, X.G. Zhao, H.S. Friedman, D.D. Bigner, A pilot study: 131I- Antitenascin monoclonal antibody 81C6 to deliver a 44-Gy resection cavity boost, Neuro-Oncol 10 (2008) 182–189, https://doi.org/10.1215/15228517-2007-053.

[48] P. Riva, G. Franceschi, 131I Radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma: phase I and II study, Acta Oncol. 38 (1999) 351–359, https://doi.org/10.1080/028418699431438.

[49] P. Riva, G. Franceschi, A. Arista, M. Frattarelli, N. Riva, A.M. Cremonini, G. Giuliani, M. Casi, Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience, Cancer 80 (1997) 2733–2742, https://doi.org/10.1002/SICI)1097-0142 (19971215)80:12<+2733::AID-CNCR53>3.0.CO;2-9.

[50] S. Sur, M. Khatun, R. Steele, T.S. Isbell, R. Ray, R.B. Ray, Exosomes from COVID-19 patients carry tenascin-C and fibrinogen-β in triggering inflammatory signals in cells of distant organ, Int. J. Mol. Sci. 22 (2021) 3184, https://doi.org/10.3390/ijms22063184.

[51] M.T. Meijer, F. Uhel, O.L. Cremer, M.J. Schultz, T. Van Der Poll, Tenascin C plasma levels in critically ill patients with or without sepsis: a multicenter observational study, Shock 54 (2020) 62–69, https://doi.org/10.1097/SHK.00000000000001481.

[52] M.T. Meijer, A.F. De Vos, H. Peters Sengers, B.P. Scicluna, J.J. Roelofs, C. Abou Fayçal, F. Uhel, G. Orend, T. Van Der Poll, Tenascin C has a modest protective effect on acute lung pathology during methicillin-resistant staphylococcus aureus- induced pneumonia in mice, Microbiol. Spectr. 9 (2021) e00207–e00221, https://doi.org/10.1128/Spectrum.00207.21.

[53] J. Satta, J. Melkko, R. Pöllänen, J. Tuukkanen, P. Pääkkö, P. Ohtonen, A. Mennander, Y. Soini, Progression of human aortic valve stenosis is associated with tenascin-C expression, J. Am. Coll. Cardiol. 39 (2002) 96–101, https://doi.org/10.1016/S0735-1097(01)01705-3.

[54] H. Zeng, D. Chen, J. Yan, Q. Yang, Q. Han, S. Li, O. Cheng, Proteomic characteristics of bronchoalveolar lavage fluid in critical COVID-19 patients, FEBS. J. 288 (2021) 5190–5200, https://doi.org/10.1111/febs.15609.

[55] Z. Sun, I. Velázquez-Quesada, D. Murdamotooh, C. Ahowess, A. Yilmaz, C. Spenlé, G. Averous, W. Erne, F. Oberndorfer, A. Oszwald, R. Kain, C. Bourdon, P. Mangin, C. Deligne, K. Midwood, C. Abou-Faycal, O. Lefebvre, A. Klein, M. van der Heyden, M.P. Chenard, G. Christofori, C. Mathelin, T. Loustau, T. Hussenet, G. Orend, Tenascin-C increases lung metastasis by impacting blood vessel invasions, Matrix. Biol. 83 (2019) 26–47, https://doi.org/10.1016/j.matbio.2019.07.001.

[56] O. De Wever, Q. Nguyen, L. Van Hoorde, M. Bracke, E. Bruyneel, C. Gespach, M. Mareel, Tenascin-C and SF/HGF produced by myofibroblasts *in vitro* provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac, FASEB J. 18 (2004) 1016–1018, https://doi.org/10.1096/fj.03-1101fje.

[57] A. Siri, B. Carnemolla, M. Saginati, A. Leprini, G. Casari, F. Baralle, L. Zardi, Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies, Nucleic Acids. Res. 19 (1991) 525–531, https://doi.org/10.1093/nar/19.3.525.

[58] P. Riva, M. Frattarelli, S. Lazzari, N. Riva, G. Giuliani, M. Casi, G. Sarti, G. Guiducci, G. Gioretti, R. Gentile, M. Santimaria, E. Jermann, H.R. Maeke, Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study, Clin. Cancer Res. 5 (1999) 3275s–3280s.

[59] P. Riva, G. Franceschi, M. Frattarelli, N. Riva, A.M. Guiducci, Cremonini, G. Giuliani, M. Casi, R. Gentile, Radioimmunotherapy of glioblastoma by using 1-131 and Y-90 labeled antitenascin monoclonal antibodies, in: H. Bergmann, H. Köhn, H. Sinzinger (Eds.), Radioactive Isotopes in Clinical Medicine and Research XXIII, Birkhäuser Basel, Basel, 1999, pp. 59–63, https://doi.org/10.1007/978-3-0438-8782-3 8.

[60] A. Boiardi, M. Eoli, A. Salmaggi, E. Lamperti, A. Botturi, G. Broggi, L. Bissola, G. Finocchiaro, A. Silvani, Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma, J. Neurooncol. 75 (2005) 215–220, https://doi.org/10.1007/s11060-005-3030-x.

[61] C. Bailly, A. Vidal, C. Bonnemaire, F. Kraeber-Bodéré, M. Chérel, A. Pallardy, C. Rousseau, E. Garcia, F. Lacoeuille, F. Hindré, S. Valable, M. Bernaudin, C. Bodet-Milin, M. Bourgeois, Potential for nuclear medicine therapy for glioblastoma treatment, Front. Pharmacol. 10 (2019) 772, https://doi.org/10.3389/fphar.2019.00772.

[62] G. Paganelli, C. Grana, M. Chinol, M. Cremonesi, C. De Cicco, F. De Braud, C. Robertson, S. Zurrida, C. Casadio, S. Zoboli, A.G. Siccardi, U. Veronesi, Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin, Eur. J. Nucl. Med. Mol. Imaging 26 (1999) 348–357, https://doi.org/10.1007/s002590050397.
[63] T. Tsunoda, H. Inada, I. Kalembeyi, K. Imanaka-Yoshida, M. Sakakibara, R. Okada, K. Katsuta, T. Sakakura, Y. Majima, T. Yoshida, Involvement of large tenascin-C splice variants in breast cancer progression, Am. J. Pathol. 162 (2003) 1857–1867, https://doi.org/10.1016/S0002-9440(10)64320-9.

[64] M. Sato, T. Toyozaki, K. Odaka, T. Uehara, Y. Arano, H. Hasegawa, K. Yoshida, K. Imanaka-Yoshida, T. Yoshida, M. Hiroe, H. Tadokoro, T. Irie, S. Tanada, I. Komuro, Detection of experimental autoimmune myocarditis in rats by 111 in monoclonal antibody specific for tenascin-C, Circulation 106 (2002) 1397–1402, https://doi.org/10.1161/01.CIR.0000027823.07104.86.

[65] N. Kobayashi, K. Odaka, T. Uehara, K. Imanaka-Yoshida, Y. Kato, H. Oyama, H. Tadokoro, H. Akizawa, S. Tanada, M. Hiroe, T. Fukumura, I. Komuro, Y. Arano, T. Yoshida, T. Irie, Toward in vivo imaging of heart disease using a radiolabeled single-chain Fv fragment targeting tenascin-C, Anal. Chem. 83 (2011) 9123–9130, https://doi.org/10.1021/ac202159p.

[66] R. De Santis, A.M. Anastasi, V. D'Alessio, A. Pelliccia, C. Albertoni, A. Rosi, B. Leoni, R. Lindstedt, F. Petronzelli, M. Dani, A. Verdoliva, A. Ippolito, N. Campanile, V. Manfredi, A. Esposito, G. Cassani, M. Chinol, G. Paganelli, P. Carminati, Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioimmunoTherapy (PAGRIT), Br. J. Cancer 88 (2003) 996–1003, https://doi.org/10.1038/sj.bjc.6600818.

[67] G. Gritti, A. Gianatti, F. Petronzelli, R. De Santis, C. Pavoni, R.L. Rossi, L. Cattaneo, L.G. Spagnoli, S. Ferroni, A. Rossi, A.M. Barbui, A. Rambaldi, Evaluation of tenascin-C by tetatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy, Oncotarget. 9 (2018) 9766–9775, https://doi.org/10.18632/ovios.105.14934.

[68] G. Giannini, F.M. Milazzo, G. Battistuzzi, R. De Santis, A.M. Anastasi, F. Petronzelli, C. Albertoni, L. Tei, L. Leone, L. Salvini, R. De Santis, Synthesis and preliminary *in vitro* evaluation of DOTA-tenatumomab conjugates for theranostatic applications in tenascin expressing tumors, Bioorg. Med. Chem. 27 (2019) 3248–3253, https://doi.org/10.1016/j.bmc.2019.05.047.

[69] A. Tiwari, J. Ram, M. Luthra-Guptasarma, Targeting the fibronectin type III repeats in tenascin-C inhibits epithelial-mesenchymal transition in the context of posterior capsular opacification, Invest. Ophthalmol. Vis. Sci. 56 (2015) 272–283, https://doi.org/10.1167/iovs.105.14934.

[70] B.B. Mehta, A. Tiwari, S. Sharma, A. Shukla, M. Sharma, R.K. Vasishta, R.K. Sen, A. Sharma, M. Luthra-Guptasarma, Amelioration of collagen antibody induced arthritis in mice by an antibody directed against the tenascin type III repeats of tenascin-C, Int. Immunopharmacol. 58 (2018) 15–23, https://doi.org/10.1016/j.intimp.2018.02.022.

[71] F. Petronzelli, A. Pelliccia, A.M. Anastasi, V. D'Alessio, C. Albertoni, A. Rosi, B. Leoni, C. De Angelis, G. Paganelli, G. Palombo, M. Dani, P. Carminati, R. De Santis, Improved tumor targeting by combined use of two antitenascin antibodies, Clin. Cancer Res. 11 (2005) 7137s–7145s, https://doi.org/10.1158/1078-0432.CCR-000047.

[72] G. Akabani, D.A. Reardon, R.E. Coleman, T.Z. Wong, S.D. Metzler, J.E. Bowsher, D.P. Barboriak, J.M. Provenzale, K.L. Greer, D. DeLong, H.S. Friedman, A. H. Friedman, X.G. Zhao, C.N. Pegram, R.E. McLendon, D.D. Bigner, M. R. Zalutsky, Dosimetry and radiographic analysis of 131I-labeled Anti&Tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study, J. Nucl. Med. 46 (2005) 1042–1051.

[73] D.A. Reardon, G. Akabani, R.E. Coleman, A.H. Friedman, H.S. Friedman, J. E. Herndon, R.E. McLendon, C.N. Pegram, R.E. Provenzale, J.A. Quinn, J.N. Rich, J.J. Vredenburgh, A. Desjardins, S. Guruangan, M. Badruddoja, J.M. Dowell, T. Z. Wong, X.G. Zhao, M.R. Zalutsky, D.D. Bigner, Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results, J. Clin. Oncol. 24 (2006) 115–122, https://doi.org/10.1200/JCO.2005.03.4082.

[74] D.A. Rizzieri, G. Akabani, M.R. Zalutsky, R.E. Coleman, S.D. Metzler, J. E. Bowsher, B. Toaso, E. Anderson, A. Lagoo, S. Clayton, C.N. Pegram, J. O. Moore, J.P. Gockerman, C. DeCastro, C. Gaspareto, N.J. Chao, D.D. Bigner, Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma, Blood 104 (2004) 642–648, https://doi.org/10.1182/blood-2003-12-4624.

[75] M.R. Zalutsky, D.A. Reardon, G. Akabani, R.E. Coleman, A.H. Friedman, H. S. Friedman, R.E. McLendon, T.Z. Wong, D.D. Bigner, Clinical experience with α-particle-emitting 211 at: treatment of recurrent brain tumor patients with 211 at- labeled chimeric antitenascin monoclonal antibody 81C6, J. Nucl. Med. 49 (2008) 30–38, https://doi.org/10.2967/jnmed.107.046938.

[76] P. Riva, A. Arista, C. Sturiale, G. Moscatelli, V. Tison, M. Mariani, E. Seccamani, S. Lazzari, L. Fagioli, G. Franceschi, G. Sarti, N. Riva, P.G. Natali, L. Zardi, G. A. Scassellati, Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2, Int. J. Cancer 51 (1992) 7–13, https://doi.org/10.1002/ijc.2910510103.

[77] K.L. Gutbrodt, C. Schliemann, L. Giovannoni, K. Frey, T. Pabst, W. Klapper, W. E. Berdel, D. Neri, Antibody-based delivery of interleukin-2 to neovascularity has potent activity against acute myeloid leukemia, Sci. Transl. Med. (2013) 5, https://doi.org/10.1126/scitranslmed.3006221.

[78] C. Schliemann, A. Wiedmer, M. Pedretti, M. Szczepanowski, W. Klapper, D. Neri, Three clinical-stage tumor targeting antibodies release differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma, Leuk. Res. 33 (2009) 1718–1722, https://doi.org/10.1016/j.leukres.2009.06.025.

[79] A. Berndt, R. Köllner, P. Richter, M. Franz, A. Voigt, A. Berndt, A. Borsi, R. Giavazzi, D. Neri, H. Kosmehl, A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP

format antibodies, Histochem. Cell Biol. 133 (2010) 467–475, https://doi.org/10.10107/s00418-010-0685-y.

[80] M. Pedretti, C. Verpelli, J. Märlind, G. Bertani, C. Sala, D. Neri, L. Bello, Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma, Br. J. Cancer 103 (2010) 827–836. https://doi.org/10.1038/sj.bjc.6605832.

[81] K. Frey, M. Fiechter, K. Schwager, B. Belloni, J.M. Barysch, D. Neri, R. Dummer, Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions, Exp. Dermatol. 20 (2011) 685–688, https://doi.org/10.1111/j.1600-6252.2011.01314.x.

[82] K. Schwager, A. Vila, C. Rösli, D. Neri, M. Rösli-Khabas, G. Moser, A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer, Head. Neck. Oncol. 3 (2011), https://doi.org/10.1186/1758-3284-3-25.

[83] L. Aloj, L. D'Ambrosio, M. Aurilio, R. Marreno, D. Neri, H.D. Menssen, L. Giovannoni, F. Di Gennaro, C. Caraco, M. Arcamone, F. Frigeri, A. Pinto, S. Lastoria, Preliminary evaluation of radioimmunotherapy with Tenarad, a 1-131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin lymphoma, J. Clin. Oncol. 29 (2011) 8063, https://doi.org/10.1200/jco.2011.29.15_suppl_8063.

[84] L. Aloj, L. D'Ambrosio, M. Aurilio, A. Morisco, F. Frigeri, C. Caraco', F. Di Gennaro, G. Capobianco, L. Giovannoni, H.D. Menssen, D. Neri, A. Pinto, S. Lastoria, Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma, Eur. J. Nucl. Med. Mol. Mol. Imaging 41 (2014) 867–877, https://doi.org/10.1007/s00259-013-2658-6.

[85] C. Catania, M. Maur, R. Berardi, A. Rocca, A.M.D. Giacomo, G. Spitaleri, C. Masini, C. Pierantoni, R. González-Iglesias, G. Zigon, A. Tascotti, L. Giovannoni, V. Lovato, G. Elia, H.D. Menssen, D. Neri, S. Cascini, P.F. Conte, F. de Braud, The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer, Cell Adhes. Migr. 9 (2015) 14–21, https://doi.org/10.4161/19336918.2014.0383785.

[86] J. Märlind, M. Kaspar, E. Trachsel, R. Sommavilla, S. Hindle, C. Bacci, L. Giovannoni, D. Neri, Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy, Clin. Cancer Res. 14 (2008) 6515–6524, https://doi.org/10.1158/1078-0432.CCR-07-5041.

[87] C. Schliemann, K.L. Gutbrodt, A. Kerkhoff, M. Pohlen, S. Wiebe, G. Silling, L. Angenendt, T. Kessler, R.M. Mesters, L. Giovannoni, M. Schäfers, B. Altvater, C. Rossig, I. Grünewald, E. Wardelmann, G. Köhler, D. Neri, M. Stelljes, W. E. Berdel, Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation, Cancer Immunol. Res. 3 (2015) 547–556, https://doi.org/10.1158/2326-6066.CIR-14-0179.

[88] D.A. Heuveling, R. de Bree, D.J. Vugs, M.C. Huisman, L. Giovannoni, O. S. Hoekstra, C.R. Leemans, D. Neri, G.A.M.S. van Dongen, Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients, J. Nucl. Med. 54 (2013) 397–401, https://doi.org/10.2967/jnmed.112.111310.

[89] A.F. Berdel, L. Ruhnke, L. Angenendt, M. Wermke, C. Röllig, J.H. Mikesch, A. Scheller, T. Hemmerle, M. Matasci, K. Wethmar, T. Kessler, M. Gerwing, D. Hescheler, M. Schäfers, W. Hartmann, B. Altvater, C. Rossig, M. Bornhäuser, G. Lenz, M. Stelljes, B. Rueter, D. Neri, W.E. Berdel, C. Schliemann, Using stromal-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse, Blood Adv. 6 (2022) 3684–3696, https://doi.org/10.1182/bloodadvances.2021006909.

[90] M. Silacci, S. Brack, G. Schirru, J. Märlind, A. Ettorre, A. Merlo, F. Viti, D. Neri, Design, construction, and characterization of a large synthetic human antibody phage display library, Proteomics. 5 (2005) 2340–2350, https://doi.org/10.1002/pmc.20041273.

[91] M. Silacci, Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors *in vivo*, Protein Eng. Des. Sel. 19 (2006) 471–478, https://doi.org/10.1093/protein/gzl033.

[92] T. von Lukowicz, M. Silacci, M.T. Wyss, E. Trachsel, C. Lohmann, A. Buck, T. F. Luscher, D. Neri, C.M. Matter, Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo, J. Nucl. Med. 48 (2007) 582–587, https://doi.org/10.2967/jnmed.106.036046.

[93] L. Zhang, Y. Wang, K.T. Homan, S.M. Gaudette, A.J. McCluskey, Y. Chan, J. Murphy, M. Abdalla, C.M. Nelson, V.Z. Sun, J.E. Erickson, H.L. Knight, A. Clabbers, A.J.S. Sterman, S. Mitra, The alternatively spliced d domain of tenascin c in a preclinical model of inflammatory bowel disease, Mol. Imaging. (2002), https://doi.org/10.1007/s11307-022-01758-6.

[94] L. Nadal, R. Corbellari, A. Villa, T. Weiss, M. Weller, D. Neri, R. De Luca, Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors *in vivo*, MAbS 12 (2020) 1836713, https://doi.org/10.1080/19420862.2020.1836713.

[95] J. Ozanne, M. Lewis, A. Schwenzer, D. Kurian, J. Brady, D. Pritchard, G. McLachlan, C. Farquharson, K.S. Midwood, Extracellular matrix complexity in biomarker studies: a novel assay detecting total serum tenascin-C reveals different distribution to isoform-specific assays, Front. Immunol. 14 (2023) 1275361, https://doi.org/10.3389/fimmu.2023.1275361.

[96] S.R. Aungier, A.J. Cartwright, A. Schwenzer, J.L. Marshall, M.R. Dyson, P. Slavny, K. Parthiban, A. Karatt-Vellatt, I. Sahbudin, E. Culbert, P. Hextall, F.I. Clanchy, R. Williams, B.D. Marsden, K. Raza, A. Filer, C.D. Buckley, J. McCafferty, K. S. Midwood, Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy? Ann. Rheum. Dis. 78 (2019) 186–191, https://doi.org/10.1136/annrheumdis-2018-214294.
[63] T. Tsunoda, H. Inada, I. Kalembeyi, K. Imanaka-Yoshida, M. Sakakibara, R. Okada, K. Katsuta, T. Sakakura, Y. Majima, T. Yoshida, Involvement of large tenascin-C splice variants in breast cancer progression, Am. J. Pathol. 162 (2003) 1857–1867, https://doi.org/10.1016/S0002-9440(10)64320-9.

[64] M. Sato, T. Toyozaki, K. Odaka, T. Uehara, Y. Arano, H. Hasegawa, K. Yoshida, K. Imanaka-Yoshida, T. Yoshida, M. Hiroe, H. Tadokoro, T. Irie, S. Tanada, I. Komuro, Detection of experimental autoimmune myocarditis in rats by 111 in monoclonal antibody specific for tenascin-C, Circulation 106 (2002) 1397–1402, https://doi.org/10.1161/01.CIR.0000027823.07104.86.

[65] N. Kobayashi, K. Odaka, T. Uehara, K. Imanaka-Yoshida, Y. Kato, H. Oyama, H. Tadokoro, H. Akizawa, S. Tanada, M. Hiroe, T. Fukumura, I. Komuro, Y. Arano, T. Yoshida, T. Irie, Toward in vivo imaging of heart disease using a radiolabeled single-chain Fv fragment targeting tenascin-C, Anal. Chem. 83 (2011) 9123–9130, https://doi.org/10.1021/ac202159p.

[66] R. De Santis, A.M. Anastasi, V. D'Alessio, A. Pelliccia, C. Albertoni, A. Rosi, B. Leoni, R. Lindstedt, F. Petronzelli, M. Dani, A. Verdoliva, A. Ippolito, N. Campanile, V. Manfredi, A. Esposito, G. Cassani, M. Chinol, G. Paganelli, P. Carminati, Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioimmunoTherapy (PAGRIT), Br. J. Cancer 88 (2003) 996–1003, https://doi.org/10.1038/sj.bjc.6600818.

[67] G. Gritti, A. Gianatti, F. Petronzelli, R. De Santis, C. Pavoni, R.L. Rossi, L. Cattaneo, L.G. Spagnoli, S. Ferroni, A. Rossi, A.M. Barbui, A. Rambaldi, Evaluation of tenascin-C by tetatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy, Oncotarget. 9 (2018) 9766–9775, https://doi.org/10.18632/ovios.105.14934.

[68] G. Giannini, F.M. Milazzo, G. Battistuzzi, R. De Santis, A.M. Anastasi, F. Petronzelli, C. Albertoni, L. Tei, L. Leone, L. Salvini, R. De Santis, Synthesis and preliminary *in vitro* evaluation of DOTA-tenatumomab conjugates for theranostatic applications in tenascin expressing tumors, Bioorg. Med. Chem. 27 (2019) 3248–3253, https://doi.org/10.1016/j.bmc.2019.05.047.

[69] A. Tiwari, J. Ram, M. Luthra-Guptasarma, Targeting the fibronectin type III repeats in tenascin-C inhibits epithelial-mesenchymal transition in the context of posterior capsular opacification, Invest. Ophthalmol. Vis. Sci. 56 (2015) 272–283, https://doi.org/10.1167/iovs.105.14934.

[70] B.B. Mehta, A. Tiwari, S. Sharma, A. Shukla, M. Sharma, R.K. Vasishta, R.K. Sen, A. Sharma, M. Luthra-Guptasarma, Amelioration of collagen antibody induced arthritis in mice by an antibody directed against the tenascin type III repeats of tenascin-C, Int. Immunopharmacol. 58 (2018) 15–23, https://doi.org/10.1016/j.intimp.2018.02.022.

[71] F. Petronzelli, A. Pelliccia, A.M. Anastasi, V. D'Alessio, C. Albertoni, A. Rosi, B. Leoni, C. De Angelis, G. Paganelli, G. Palombo, M. Dani, P. Carminati, R. De Santis, Improved tumor targeting by combined use of two antitenascin antibodies, Clin. Cancer Res. 11 (2005) 7137s–7145s, https://doi.org/10.1158/1078-0432.CCR-2004-0007.

[72] G. Akabani, D.A. Reardon, R.E. Coleman, T.Z. Wong, S.D. Metzler, J.E. Bowsher, D.P. Barboriak, J.M. Provenzale, K.L. Greer, D. DeLong, H.S. Friedman, A. H. Friedman, X.G. Zhao, C.N. Pegram, R.E. McLendon, D.D. Bigner, M. R. Zalutsky, Dosimetry and radiographic analysis of 131I-labeled Anti&Tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study, J. Nucl. Med. 46 (2005) 1042–1051.

[73] D.A. Reardon, G. Akabani, R.E. Coleman, A.H. Friedman, H.S. Friedman, J. E. Herndon, R.E. McLendon, C.N. Pegram, J.M. Provenzale, J.A. Quinn, J.N. Rich, J.J. Vredenburgh, A. Desjardins, S. Guruangan, M. Badruddoja, J.M. Dowell, T. Z. Wong, X.G. Zhao, M.R. Zalutsky, D.D. Bigner, Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results, J. Clin. Oncol. 24 (2006) 115–122, https://doi.org/10.1200/JCO.2005.03.4082.

[74] D.A. Rizzieri, G. Akabani, M.R. Zalutsky, R.E. Coleman, S.D. Metzler, J. E. Bowsher, B. Toaso, E. Anderson, A. Lagoo, S. Clayton, C.N. Pegram, J. O. Moore, J.P. Gockerman, C. DeCastro, C. Gaspareto, N.J. Chao, D.D. Bigner, Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma, Blood 104 (2004) 642–648, https://doi.org/10.1182/blood-2003-12-4624.

[75] M.R. Zalutsky, D.A. Reardon, G. Akabani, R.E. Coleman, A.H. Friedman, H. S. Friedman, R.E. McLendon, T.Z. Wong, D.D. Bigner, Clinical experience with α-particle-emitting 211 at: treatment of recurrent brain tumor patients with 211 at- labeled chimeric antitenascin monoclonal antibody 81C6, J. Nucl. Med. 49 (2008) 30–38, https://doi.org/10.2967/jnmed.107.046938.

[76] P. Riva, A. Arista, C. Sturiale, G. Moscatelli, V. Tison, M. Mariani, E. Seccamani, S. Lazzari, L. Fagioli, G. Franceschi, G. Sarti, N. Riva, P.G. Natali, L. Zardi, G. A. Scassellati, Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2, Int. J. Cancer 51 (1992) 7–13, https://doi.org/10.1002/ijc.2910510103.

[77] K.L. Gutbrodt, C. Schliemann, L. Giovannoni, K. Frey, T. Pabst, W. Klapper, W. E. Berdel, D. Neri, Antibody-based delivery of interleukin-2 to neovascularity has potent activity against acute myeloid leukemia, Sci. Transl. Med. (2013) 5, https://doi.org/10.1126/scitranslmed.3006221.

[78] C. Schliemann, A. Wiedmer, M. Pedretti, M. Szczepanowski, W. Klapper, D. Neri, Three clinical-stage tumor targeting antibodies release differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma, Leuk. Res. 33 (2009) 1718–1722, https://doi.org/10.1016/j.leukres.2009.06.025.

[79] A. Berndt, R. Köllner, P. Richter, M. Franz, A. Voigt, A. Berndt, A. Borsi, R. Giavazzi, D. Neri, H. Kosmehl, A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP

format antibodies, Histochem. Cell Biol. 133 (2010) 467–475, https://doi.org/10.1010/s00418-010-0685-y.

[80] M. Pedretti, C. Verpelli, J. Märlind, G. Bertani, C. Sala, D. Neri, L. Bello, Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma, Br. J. Cancer 103 (2010) 827–836. https://doi.org/10.1038/sj.bjc.6605832.

[81] K. Frey, M. Fiechter, K. Schwager, B. Belloni, J.M. Barysch, D. Neri, R. Dummer, Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions, Exp. Dermatol. 20 (2011) 685–688, https://doi.org/10.1111/j.1600-6252.2011.01314.x.

[82] K. Schwager, A. Vila, C. Rösli, D. Neri, M. Rösli-Khabas, G. Moser, A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer, Head. Neck. Oncol. 3 (2011), https://doi.org/10.1186/1758-3284-3-25.

[83] L. Aloj, L. D'Ambrosio, M. Aurilio, R. Marreno, D. Neri, H.D. Menssen, L. Giovannoni, F. Di Gennaro, C. Caraco, M. Arcamone, F. Frigeri, A. Pinto, S. Lastoria, Preliminary evaluation of radioimmunotherapy with Tenarad, a 1-131 labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin lymphoma, J. Clin. Oncol. 29 (2011) 8063, https://doi.org/10.1200/jco.2011.29.15_suppl_8063.

[84] L. Aloj, L. D'Ambrosio, M. Aurilio, A. Morisco, F. Frigeri, C. Caraco', F. Di Gennaro, G. Capobianco, L. Giovannoni, H.D. Menssen, D. Neri, A. Pinto, S. Lastoria, Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma, Eur. J. Nucl. Med. Mol. Mol. Imaging 41 (2014) 867–877, https://doi.org/10.1007/s00259-013-2658-6.

[85] C. Catania, M. Maur, R. Berardi, A. Rocca, A.M.D. Giacomo, G. Spitaleri, C. Masini, C. Pierantoni, R. González-Iglesias, G. Zigon, A. Tascotti, L. Giovannoni, V. Lovato, G. Elia, H.D. Menssen, D. Neri, S. Cascini, P.F. Conte, F. de Braud, The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer, Cell Adhes. Migr. 9 (2015) 14–21, https://doi.org/10.4161/19336918.2014.0383785.

[86] J. Märlind, M. Kaspar, E. Trachsel, R. Sommavilla, S. Hindle, C. Bacci, L. Giovannoni, D. Neri, Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy, Clin. Cancer Res. 14 (2008) 6515–6524, https://doi.org/10.1158/1078-0432.CCR-07-5041.

[87] C. Schliemann, K.L. Gutbrodt, A. Kerkhoff, M. Pohlen, S. Wiebe, G. Silling, L. Angenendt, T. Kessler, R.M. Mesters, L. Giovannoni, M. Schäfers, B. Altvater, C. Rossig, I. Grünewald, E. Wardelmann, G. Köhler, D. Neri, M. Stelljes, W. E. Berdel, Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation, Cancer Immunol. Res. 3 (2015) 547–556, https://doi.org/10.1158/2326-6066.CIR-14-0179.

[88] D.A. Heuveling, R. de Bree, D.J. Vugs, M.C. Huisman, L. Giovannoni, O. S. Hoekstra, C.R. Leemans, D. Neri, G.A.M.S. van Dongen, Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients, J. Nucl. Med. 54 (2013) 397–401, https://doi.org/10.2967/jnmed.112.111310.

[89] A.F. Berdel, L. Ruhnke, L. Angenendt, M. Wermke, C. Röllig, J.H. Mikesch, A. Scheller, T. Hemmerle, M. Matasci, K. Wethmar, T. Kessler, M. Gerwing, D. Hescheler, M. Schäfers, W. Hartmann, B. Altvater, C. Rossig, M. Bornhäuser, G. Lenz, M. Stelljes, B. Rueter, D. Neri, W.E. Berdel, C. Schliemann, Using stromal-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse, Blood Adv. 6 (2022) 3684–3696, https://doi.org/10.1182/bloodadvances.2021006909.

[90] M. Silacci, S. Brack, G. Schirru, J. Märlind, A. Ettorre, A. Merlo, F. Viti, D. Neri, Design, construction, and characterization of a large synthetic human antibody phage display library, Proteomics. 5 (2005) 2340–2350, https://doi.org/10.1002/pmc.20041273.

[91] M. Silacci, Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors *in vivo*, Protein Eng. Des. Sel. 19 (2006) 471–478, https://doi.org/10.1093/protein/gzl033.

[92] T. von Lukowicz, M. Silacci, M.T. Wyss, E. Trachsel, C. Lohmann, A. Buck, T. F. Luscher, D. Neri, C.M. Matter, Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo, J. Nucl. Med. 48 (2007) 582–587, https://doi.org/10.2967/jnmed.106.036046.

[93] L. Zhang, Y. Wang, K.T. Homan, S.M. Gaudette, A.J. McCluskey, Y. Chan, J. Murphy, M. Abdalla, C.M. Nelson, V.Z. Sun, J.E. Erickson, H.L. Knight, A. Clabbers, A.J.S. Sterman, S. Mitra, The alternatively spliced d domain of tenascin c in a preclinical model of inflammatory bowel disease, Mol. Imaging. (2002), https://doi.org/10.1007/s11307-022-01758-6.

[94] L. Nadal, R. Corbellari, A. Villa, T. Weiss, M. Weller, D. Neri, R. De Luca, Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors *in vivo*, MAbS 12 (2020) 1836713, https://doi.org/10.1080/19420862.2020.1836713.

[95] J. Ozanne, M. Lewis, A. Schwenzer, D. Kurian, J. Brady, D. Pritchard, G. McLachlan, C. Farquharson, K.S. Midwood, Extracellular matrix complexity in biomarker studies: a novel assay detecting total serum tenascin-C reveals different distribution to isoform-specific assays, Front. Immunol. 14 (2023) 1275361, https://doi.org/10.3389/fimmu.2023.1275361.

[96] S.R. Aungier, A.J. Cartwright, A. Schwenzer, J.L. Marshall, M.R. Dyson, P. Slavny, K. Parthiban, A. Karatt-Vellatt, I. Sahbudin, E. Culbert, P. Hextall, F.I. Clanchy, R. Williams, B.D. Marsden, K. Raza, A. Filer, C.D. Buckley, J. McCafferty, K. S. Midwood, Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy? Ann. Rheum. Dis. 78 (2019) 186–191, https://doi.org/10.1136/annrheumdis-2018-214294.
[97] C. Deligne, D. Murdamoothoo, A.N. Gammage, M. Gschwandtner, W. Erne, T. Loustau, A.M. Marzeda, R. Carapito, N. Paul, I. Velazquez-Quesada, I. Mazzier, Z. Sun, G. Orend, K.S. Midwood, Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype. Cancer Immunol. Res. 8 (2020) 368–382, https://doi.org/10.1158/2326-6066.CIR-19-0276.

[98] N. Jailkhani, J.R. Ingram, M. Rashidian, S. Rickelt, C. Tian, H. Mak, Z. Jiang, H. L. Ploegh, R.O. Hynes, Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix, Proc. Natl. Acad. Sci. 116 (2019) 14181–14190, https://doi.org/10.1073/pnas.1817442116.

[99] P. Riva, C. Sturiale, A. Arista, G. Franceschi, N. Riva, R. Rossitti, M. Casi, 263 Intralesional radioimmunotherapy of malignant gliomas as adjuvant setting in newly diagnosed tumour or as rescue treatment in recurrent lesions, Eur. J. Cancer 31 (1995) S58, https://doi.org/10.1016/0959-8049(95)95521-7.

[100] D.D. Bigner, M.T. Brown, A.H. Friedman, R.E. Coleman, G. Akabani, H. S. Friedman, W.L. Thorstad, R.E. McLendon, S.H. Bigner, X.G. Zhao, C.N. Pegram, C.J. Wikstrand, J.E. Herndon, N.A. Vick, N. Paleologos, I. Cokgor, J. M. Provenzale, M.R. Zalutsky, Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results, J. Clin. Oncol. 16 (1998) 2202–2212, https://doi.org/10.1200/JCO.1998.16.6.2202.

[101] Z. Yao, K. Garmestani, K.J. Wong, L.S. Park, E. Dadachova, A. Yordanov, T. A. Waldmann, W.C. Eckerman, C.H. Paik, J.A. Carrasquillo, Comparative Cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody, J. Nucl. Med. 42 (2001) 1538–1544.

[102] X. He, G.E. Archer, C.J. Wikstrand, S.L. Morrison, M.R. Zalutsky, D.D. Bigner, S. K. Batra, Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin, J. Neuroimmunol. 52 (1994) 127–137, https://doi.org/10.1016/0165-5728(94)90106-6.

[103] D.R. Goulet, M.J. Watson, S.H. Tam, A. Zwolak, M.M. Chiu, W.M. Atkins, A. Nath, Toward a combinatorial approach for the prediction of IgG half-life and clearance, Drug Metab. Dispos. 46 (2018) 1900–1907, https://doi.org/10.1124/dmd.118.08193.

[104] C. Passey, S. Suryawanshi, K. Sanghavi, M. Gupta, Reporting, visualization, and modeling of immunogenicity data to assess its impact on pharmacokinetics, efficacy, and safety of monoclonal antibodies, AAPS J. 20 (2018) 35, https://doi.org/10.1208/s12248-018-0194-9.

[105] M.A. Bourdon, C.J. Wikstrand, H. Furthmayr, T.J. Matthews, D.D. Bigner, Human glioma mesenchymal extracellular matrix antigen defined by monoclonal antibody, Cancer Res. 43 (1983) 2796–2805.

[106] V.S. Rybchenko, T.K. Aliev, A.A. Panina, M.P. Kirpichnikov, D.A. Dolgikh, Targeted cytokine delivery for cancer treatment: engineering and biological effects, Pharmaceutics. 15 (2023) 336, https://doi.org/10.3390/pharmaceutics15020336.

[107] R.A. Reisfeld, S.D. Gillies, Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy, J. Clin. Lab. Anal. 10 (1996) 160–166, https://doi.org/10.1002/(SIC)1098-2825(1996)10:3<160::AID-JCLA9-3.0.CO;2-F.

[108] C. Schliemann, T. Kessler, A. Berdel, T. Hemmerle, L. Angenendt, B. Altvater, C. Rossing, J.H. Milkesch, G. Lenz, M. Allen, D. Neri, M. Stelljes, W.E. Berdel, Phase I study of F16IL2 antibody–cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after alllogeneic stem cell transplantation, Br. J. Haematol. 192 (2021) e136–e154, https://doi.org/10.1111/bjh.17365.

[109] F.G. De Braud, A.C. Onofri, S.P. Cascini, M. Maur, C. Masini, P. Conte, L. Giovannoni, V. Tasciotti, Lovato, D. Neri, H.D. Menssen, Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: results from two phase Ib trials, J. Clin. Oncol. 29 (2011), https://doi.org/10.1200/jco.2011.29.15 Suppl 2595.

[110] D. Berndorff, S. Borkowski, S. Sieger, A. Rother, M. Friebe, F. Viti, C.S. Hilger, J. E. Cyr, L.M. Dinkelborg, Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate, Clin. Cancer Res. 11 (2005) 7053s–7063s, https://doi.org/10.1158/1078-0432.CCR-1004-0015.

[111] S. Hibino, K. Kato, S. Kudoh, H. Yagita, K. Okumura, Tenascin suppresses CD3-mediated T cell activation, Biochem. Biophys. Res. Commun. 250 (1998) 119–124, https://doi.org/10.1006/bbrc.1998.9258.

[112] E. Jachetti, S. Caputo, S. Mazzoleni, C.S. Brambillasca, S.M. Parigi, M. Grioni, I. S. Piras, U. Restuccia, A. Calcinotto, M. Freschi, A. Bachi, R. Galli, M. Bellone, Tenascin-C protects cancer stem-like cells from immune surveillance by arresting T-cell activation, Cancer Res. 75 (2015) 2095–2108, https://doi.org/10.1158/0008-5472.CAN-12-2346.

[113] M.D. Puente Navazo, D. Valmori, C. Rüegg, The alternatively spliced domain TfNnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production, J. Immunol. 167 (2001) 6431–6440, https://doi.org/10.4049/jimmunol.167.11.6431.

[114] C. Spenlé, T. Loustau, D. Murdamoothoo, W. Erne, S. Beghelli-de la Forest Divonne, R. Veber, L. Petti, P. Bourdely, M. Mörgelin, E.M. Brauchle, G. Cremel, V. Randrianarisoa, A. Camara, S. Rekima, S. Schaub, K. Nouhen, T. Imhof, U. Hansen, N. Paul, R. Carapito, N. Pythoud, A. Hirschler, C. Carapito, H. Dumortier, C.G. Mueller, M. Koch, K. Schenke-Layland, S. Kon, A. Sudaka, F. Anjuère, E. Van Obberghen-Schilling, G. Orend, Tenascin-C orchestrates an immune-suppressive tumor microenvironment in oral squamous cell carcinoma, Cancer Immunol. Res. 8 (2020) 1122–1138, https://doi.org/10.1158/2326-6066.CIR-20-0074.

[115] G. Behar, S. Siberer, A. Groulet, P. Chames, M. Pugniere, C. Boix, C. Sautes-Fridman, J.L. Teillaud, D. Baty, Isolation and characterization of anti-Fc RIII (CD16) llama single-domain antibodies that activate natural killer cells, Protein Eng. Des. Sel. 21 (2007) 1–10, https://doi.org/10.1093/protein/gzm064.

[116] S. Muyldermans, Nanobodies: natural single-domain antibodies, Annu. Rev. Biochem. 82 (2013) 775–797, https://doi.org/10.1146/annurev-biochem-063011-092449.

[117] D.M. Chigoho, J. Bridoux, S. Hernot, Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals, Curr. Opin. Chem. Biol. 63 (2021) 219–228, https://doi.org/10.1016/j.cbpa.2021.06.008.

[118] S.A.M. Kaeppleri, A. Jodal, M. Gotthardt, R. Schibli, M. Béhé, Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting, Mol. Pharm. 16 (2019) 3760–3769, https://doi.org/10.1021/acs.molpharmaceut.9b00271.

[119] B. Trachsel, G. Valpreda, A. Lutz, R. Schibli, L. Mu, M. Béhé, Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MKV, EJNMMI Radiopharm. Chem. 8 (2023) 21, https://doi.org/10.1186/s41181-023-00206-2.

[120] N. Jailkhani, K.R. Clauser, H.H. Mak, S. Rickelt, C. Tian, C.A. Whittaker, K. K. Tanabe, S.R. Purdy, S.A. Carr, R.O. Hynes, Proteomic profiling of extracellular matrix components from patient metastases identifies consistently elevated proteins for developing nanobodies that target primary tumors and metastases, Cancer Res. 83 (2023) 2052–2065, https://doi.org/10.1158/0008-5472.CAN-22-1532.

[121] K. Lange, M. Kammerer, M.E. Hegi, S. Grotegut, A. Dittmann, W. Huang, E. Fluri, G.W. Yip, M. Götte, C. Ruiz, G. Orend, Endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization, Cancer Res. 67 (2007) 6163–6173, https://doi.org/10.1158/0008-5472.CAN-06-3348.

[122] S. Dhaouadi, D. Murdamoothoo, A. Tounsi, W. Erne, R. Benabderrazek, Z. Benlasfar, L. Hendaoui, R. Chiquet-Ehrlichman, S. Boukaker, G. Orend, I. Hendaoui, B. Bouhaouala-Zahar, Generation and characterization of dromedary Tenascin-C and Tenascin-W specific antibodies, Biochim. Biophys. Res. Commun. 530 (2020) 471–478, https://doi.org/10.1016/j.bbrc.2020.05.077.

[123] T. Hongu, M. Pein, J. Insua-Rodríguez, E. Gutjahr, G. Mattavelli, J. Meier, K. Decker, A. Descot, M. Bozza, R. Harbott, A. Trumpp, H.P. Sinn, A. Riedel, T. Oskarsson, Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs, Nat. Cancer 3 (2022) 486–504, https://doi.org/10.1038/s43018-022-00353-6.

[124] M.Y. Kim, O.R. Kim, Y.S. Choi, H. Lee, K. Park, C.T. Lee, K.W. Kang, S. Jeong, Selection and characterization of tenascin C targeting peptide, Mol. Cells 33 (2012) 71–77, https://doi.org/10.1007/s10059-012-2214-4.

[125] T. Loustau, C. Abou-Faycal, W. Erne, P.A. Zur Wiesch, A. Ksouri, T. Imhof, M. Mörgelin, C. Li, M. Mathieu, N. Salomé, G. Crémel, S. Dhaouadi, B. Bouhaouala-Zahar, M. Koch, G. Orend, Modulating tenascin-C functions by targeting the MAtex REGulating Motif, "MAREMO.", Matrix. Biol. 108 (2022) 20–38, https://doi.org/10.1016/j.matbio.2022.02.007.

[126] T. Kang, Q. Zhu, D. Jiang, X. Feng, J. Feng, T. Jiang, J. Yao, Y. Jing, Q. Song, X. Jiang, X. Gao, J. Chen, Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for antiglioblastoma treatment, Biomaterials. 2016 (2016) 60–75, https://doi.org/10.1016/j.biomaterials.2016.05.037.

[127] P. Lingasamy, A. Tobi, M. Haugas, H. Hunt, P. Paiste, T. Asser, T. Rätsep, V. R. Kotamraju, R. Bjerkvig, T. Teesalu, Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery, Biomaterials 219 (2019) 119373, https://doi.org/10.1016/j.biomaterials.2019.119373.

[128] P. Lingasamy, A. Tobi, K. Kurm, S. Kopanchuk, A. Sudakov, M. Salumæ, T. Rätsep, T. Asser, R. Bjerkvig, T. Teesalu, Tumor-penetrating peptide for systemic targeting of Tenascin-C, Sci. Rep. 10 (2020) 5809, https://doi.org/10.1038/s4598-020-62760-y.

[129] D.A. Daniels, H. Chen, B.J. Hicke, K.M. Swiderek, L. Gold, A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment, Proc. Natl. Acad. Sci 100 (2003) 15416–15421, https://doi.org/10.1073/pnas.2136683100.

[130] L.X. Zhang, K.F. Li, H. Wang, M.J. Gu, L.S. Liu, Z.Z. Zheng, N.Y. Han, Z.J. Yang, T. Y. Fan, Preparation and in vitro evaluation of a MRI contrast agent based on aptamer-modified gadolinium-loaded liposomes for tumor targeting, AAPS PharmSciTech. 18 (2017) 1564–1571, https://doi.org/10.1208/s12249-016-0600-5.

[131] T.Y. Fan, M.J. Gu, K.F. Li, L.X. Zhang, H. Wang, L.S. Liu, Z.Z. Zheng, N.Y. Han, Z. J. Yang, *In vitro* study of novel gadolinium-loaded liposomes guided by GBI-10 aptamer for promising tumor targeting and tumor diagnosis by n&bSP;magnetic resonance imaging, Int. J. Nanomed. 5187 (2015), https://doi.org/10.2147/IJN.S84351.

[132] X.C. Chen, Y.L. Deng, Y. Lin, D.W. Pang, H. Qing, F. Qu, H.Y. Xie, Quantum dot-labeled aptamer nanoprobes specifically targeting glioma cells, Nanotechnology 19 (2008) 235105, https://doi.org/10.1088/0957-4484/19/23/235105.

[133] L. Kunfeng, D. Jiali, J. Hongwei, Y. Xianto, F. Xinmeng, L. Liyu, Z. Yi, G. Zhu, W. Yun, Z. Lihe, Y. Zhenjun, Chemical modification improves stability of DNA aptamer GBI-10 and its 1 affinity towards Tenascin-C, Org. Biomol. Chem. 14 (2016) 1–12, https://doi.org/10.1039/C5OB01898F.

[134] Q. Guo, X. He, C. Li, Y. He, Y. Peng, Yu Zhang, Y. Lu, X. Chen, Y. Zhang, Q. Chen, T. Sun, C. Jiang, Dandelion-like tailorable nanoparticles for tumor microenvironment modulation, Adv. Sci. 6 (2019) 1901430, https://doi.org/10.1002/adv.201901430.

[135] X. He, X. Chen, L. Liu, Yu Zhang, Y. Lu, Yujie Zhang, Q. Chen, C. Ruan, Q. Guo, C. Li, T. Sun, C. Jiang, Sequentially triggered nanoparticles with tumor penetration and intelligent drug release for pancreatic cancer therapy, Adv. Sci. 5 (2018) 1701070, https://doi.org/10.1002/adv.201701070.
[97] C. Deligne, D. Murdamoothoo, A.N. Gammage, M. Gschwandtner, W. Erne, T. Loustau, A.M. Marzeda, R. Carapito, N. Paul, I. Velazquez-Quesada, I. Mazzier, Z. Sun, G. Orend, K.S. Midwood, Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype. Cancer Immunol. Res. 8 (2020) 368–382, https://doi.org/10.1158/2326-6066.CIR-19-0276.

[98] N. Jailkhani, J.R. Ingram, M. Rashidian, S. Rickelt, C. Tian, H. Mak, Z. Jiang, H. L. Ploegh, R.O. Hynes, Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix, Proc. Natl. Acad. Sci. 116 (2019) 14181–14190, https://doi.org/10.1073/pnas.1817442116.

[99] P. Riva, C. Sturiale, A. Arista, G. Franceschi, N. Riva, R. Rossitti, M. Casi, 263 Intralesional radioimmunotherapy of malignant gliomas as adjuvant setting in newly diagnosed tumour or as rescue treatment in recurrent lesions, Eur. J. Cancer 31 (1995) S58, https://doi.org/10.1016/0959-8049(95)95521-7.

[100] D.D. Bigner, M.T. Brown, A.H. Friedman, R.E. Coleman, G. Akabani, H. S. Friedman, W.L. Thorstad, R.E. McLendon, S.H. Bigner, X.G. Zhao, C.N. Pegram, C.J. Wikstrand, J.E. Herndon, N.A. Vick, N. Paleologos, I. Cokgor, J. M. Provenzale, M.R. Zalutsky, Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results, J. Clin. Oncol. 16 (1998) 2202–2212, https://doi.org/10.1200/JCO.1998.16.6.2202.

[101] Z. Yao, K. Garmestani, K.J. Wong, L.S. Park, E. Dadachova, A. Yordanov, T. A. Waldmann, W.C. Eckerman, C.H. Paik, J.A. Carrasquillo, Comparative Cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody, J. Nucl. Med. 42 (2001) 1538–1544.

[102] X. He, G.E. Archer, C.J. Wikstrand, S.L. Morrison, M.R. Zalutsky, D.D. Bigner, S. K. Batra, Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin, J. Neuroimmunol. 52 (1994) 127–137, https://doi.org/10.1016/0165-5728(94)90106-6.

[103] D.R. Goulet, M.J. Watson, S.H. Tam, A. Zwolak, M.M. Chiu, W.M. Atkins, A. Nath, Toward a combinatorial approach for the prediction of IgG half-life and clearance, Drug Metab. Dispos. 46 (2018) 1900–1907, https://doi.org/10.1124/dmd.118.08193.

[104] C. Passey, S. Suryawanshi, K. Sanghavi, M. Gupta, Reporting, visualization, and modeling of immunogenicity data to assess its impact on pharmacokinetics, efficacy, and safety of monoclonal antibodies, AAPS J. 20 (2018) 35, https://doi.org/10.1208/s12248-018-0194-9.

[105] M.A. Bourdon, C.J. Wikstrand, H. Furthmayr, T.J. Matthews, D.D. Bigner, Human glioma mesenchymal extracellular matrix antigen defined by monoclonal antibody, Cancer Res. 43 (1983) 2793–2805.

[106] V.S. Rybchenko, T.K. Aliev, A.A. Panina, M.P. Kirpichnikov, D.A. Dolgikh, Targeted cytokine delivery for cancer treatment: engineering and biological effects, Pharmaceutics. 15 (2023) 336, https://doi.org/10.3390/pharmaceutics15020336.

[107] R.A. Reisfeld, S.D. Gillies, Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy, J. Clin. Lab. Anal. 10 (1996) 160–166, https://doi.org/10.1002/(SIC)1098-2825(1996)10:3<160::AID-JCLA9-3.0.CO;2-F.

[108] C. Schliemann, T. Kessler, A. Berdel, T. Hemmerle, L. Angenendt, B. Altvater, C. Rossing, J.H. Milkesch, G. Lenz, M. Allen, D. Neri, M. Stelljes, W.E. Berdel, Phase I study of F16IL2 antibody–cytokine fusion with very low-dose arac in acute myeloid leukaemia relapse after allogenous stem cell transplantation, Br. J. Haematol. 192 (2021) e136–e154, https://doi.org/10.1111/bjh.17365.

[109] F.G. De Braud, A.C. Onofri, S.P. Cascini, M. Maur, C. Masini, P.F. Conte, L. Giovannoni, V. Tasciotti, Lovato, D. Neri, H.D. Menssen, Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: results from two phase Ib trials, J. Clin. Oncol. 29 (2011), https://doi.org/10.1200/jco.2011.29.15 Suppl 2595.

[110] D. Berndorff, S. Borkowski, S. Sieger, A. Rother, M. Friebe, F. Viti, C.S. Hilger, J. E. Cyr, L.M. Dinkelborg, Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate, Clin. Cancer Res. 11 (2005) 7053s–7063s, https://doi.org/10.1158/1078-0432.CCR-1004-0015.

[111] S. Hibino, K. Kato, S. Kudoh, H. Yagita, K. Okumura, Tenascin suppresses CD3-mediated T cell activation, Biochem. Biophys. Res. Commun. 250 (1998) 119–124, https://doi.org/10.1006/bbrc.1998.9258.

[112] E. Jachetti, S. Caputo, S. Mazzoleni, C.S. Brambillasca, S.M. Parigi, M. Grioni, I. S. Piras, U. Restuccia, A. Calcinotto, M. Freschi, A. Bachi, R. Galli, M. Bellone, Tenascin-C protects cancer stem-like cells from immune surveillance by arresting T-cell activation, Cancer Res. 75 (2015) 2095–2108, https://doi.org/10.1158/0008-5472.CAN-12-2346.

[113] M.D. Puente Navazo, D. Valmori, C. Rüegg, The alternatively spliced domain TnFnl1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production, J. Immunol. 167 (2001) 6431–6440, https://doi.org/10.4049/jimmunol.167.11.6431.

[114] C. Spenlé, T. Loustau, D. Murdamoothoo, W. Erne, S. Beghelli-de la Forest Divonne, R. Veber, L. Petti, P. Bourdely, M. Mörgelin, E.M. Brauchle, G. Cremel, V. Randrianarisoa, A. Camara, S. Rekima, S. Schaub, K. Nouhen, T. Imhof, U. Hansen, N. Paul, R. Carapito, N. Pythoud, A. Hirschler, C. Carapito, H. Dumortier, C.G. Mueller, M. Koch, C. Schenke-Layland, S. Kon, A. Sudaka, F. Anjuère, E. Van Obberghen-Schilling, G. Orend, Tenascin-C orchestrates an immune-suppressive tumor microenvironment in oral squamous cell carcinoma, Cancer Immunol. Res. 8 (2020) 1122–1138, https://doi.org/10.1158/2326-6066.CIR-20-0074.

[115] G. Behar, S. Siberer, A. Groulet, P. Chames, M. Pugniere, C. Boix, C. Sautes-Fridman, J.L. Teillaud, D. Baty, Isolation and characterization of anti-Fc RIII (CD16) llama single-domain antibodies that activate natural killer cells, Protein Eng. Des. Sel. 21 (2007) 1–10, https://doi.org/10.1093/protein/gzm064.

[116] S. Muyldermans, Nanobodies: natural single-domain antibodies, Annu. Rev. Biochem. 82 (2013) 775–797, https://doi.org/10.1146/annurev-biochem-063011-092449.

[117] D.M. Chigoho, J. Bridoux, S. Hernot, Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals, Curr. Opin. Chem. Biol. 63 (2021) 219–228, https://doi.org/10.1016/j.cbpa.2021.06.008.

[118] S.A.M. Kaeppleri, A. Jodal, M. Gotthardt, R. Schibli, M. Béhé, Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting, Mol. Pharm. 16 (2019) 3760–3769, https://doi.org/10.1021/acs.molpharmaceut.9b00271.

[119] B. Trachsel, G. Valpreda, A. Lutz, R. Schibli, L. Mu, M. Béhé, Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK, EJNMMI Radiopharm. Chem. 8 (2023) 21, https://doi.org/10.1186/s41181-023-00206-2.

[120] N. Jailkhani, K.R. Clauser, H.H. Mak, S. Rickelt, C. Tian, C.A. Whittaker, K. K. Tanabe, S.R. Purdy, S.A. Carr, R.O. Hynes, Proteomic profiling of extracellular matrix components from patient metastases identifies consistently elevated proteins for developing nanobodies that target primary tumors and metastases, Cancer Res. 83 (2023) 2052–2065, https://doi.org/10.1158/0008-5472.CAN-22-1532.

[121] K. Lange, M. Kammerer, M.E. Hegi, S. Grotegut, A. Dittmann, W. Huang, E. Fluri, G.W. Yip, M. Götte, C. Ruiz, G. Orend, Endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization, Cancer Res. 67 (2007) 6163–6173, https://doi.org/10.1158/0008-5472.CAN-06-3348.

[122] S. Dhaouadi, D. Murdamoothoo, A. Tounsi, W. Erne, R. Benabderrazek, Z. Benlasfar, L. Hendaoui, R. Chiquet-Ehrlichman, S. Boukaker, G. Orend, I. Hendaoui, B. Bouhaouala-Zahar, Generation and characterization of dromedary Tenascin-C and Tenascin-W specific antibodies, Biochim. Phys. Res. Commun. 530 (2020) 471–478, https://doi.org/10.1016/j.bbrc.2020.05.077.

[123] T. Hongu, M. Pein, J. Insua-Rodríguez, E. Gutjahr, G. Mattavelli, J. Meier, K. Decker, A. Descot, M. Bozza, R. Harbott, A. Trumpp, H.P. Sinn, A. Riedel, T. Oskarsson, Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs, Nat. Cancer 3 (2022) 486–504, https://doi.org/10.1038/s43018-022-00353-6.

[124] M.Y. Kim, O.R. Kim, Y.S. Choi, H. Lee, K. Park, C.T. Lee, K.W. Kang, S. Jeong, Selection and characterization of tenascin C targeting peptide, Mol. Cells 33 (2012) 71–77, https://doi.org/10.1007/s10059-012-2214-4.

[125] T. Loustau, C. Abou-Faycal, W. Erne, P.A. Zur Wiesch, A. Ksouri, T. Imhof, M. Mörgelin, C. Li, M. Mathieu, N. Salomé, G. Crémel, S. Dhaouadi, B. Bouhaouala-Zahar, M. Koch, G. Orend, Modulating tenascin-C functions by targeting the MAtex REGulating Motif, "MAREMO.", Matrix. Biol. 108 (2022) 20–38, https://doi.org/10.1016/j.matbio.2022.02.007.

[126] T. Kang, Q. Zhu, D. Jiang, X. Feng, J. Feng, T. Jiang, J. Yao, Y. Jing, Q. Song, X. Jiang, X. Gao, J. Chen, Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for anti-glioblastoma treatment, Biomaterials. 2016 (2016) 60–75, https://doi.org/10.1016/j.biomaterials.2016.05.037.

[127] P. Lingasamy, A. Tobi, M. Haugas, H. Hunt, P. Paiste, T. Asser, T. Rätsep, V. R. Kotamraju, R. Bjerkvig, T. Teesalu, Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery, Biomaterials 219 (2019) 119373, https://doi.org/10.1016/j.biomaterials.2019.119373.

[128] P. Lingasamy, A. Tobi, K. Kurm, S. Kopanchuk, A. Sudakov, M. Salumæ, T. Rätsep, T. Asser, R. Bjerkvig, T. Teesalu, Tumor-penetrating peptide for systemic targeting of Tenascin-C, Sci. Rep. 10 (2020) 5809, https://doi.org/10.1038/s4598-020-62760-y.

[129] D.A. Daniels, H. Chen, B.J. Hicke, K.M. Swiderek, L. Gold, A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment, Proc. Natl. Acad. Sci 100 (2003) 15416–15421, https://doi.org/10.1073/pnas.2136683100.

[130] L.X. Zhang, K.F. Li, H. Wang, M.J. Gu, L.S. Liu, Z.Z. Zheng, N.Y. Han, Z.J. Yang, T. Y. Fan, Preparation and in vitro evaluation of a MRI contrast agent based on aptamer-modified gadolinium-loaded liposomes for tumor targeting, AAPS PharmSciTech. 18 (2017) 1564–1571, https://doi.org/10.1208/s12249-016-0600-5.

[131] T.Y. Fan, M.J. Gu, K.F. Li, L.X. Zhang, H. Wang, L.S. Liu, Z.Z. Zheng, N.Y. Han, Z. J. Yang, *In vitro* study of novel gadolinium-loaded liposomes guided by GBI-10 aptamer for promising tumor targeting and tumor diagnosis by&nbsp;magnetic resonance imaging, Int. J. Nanomed. 5187 (2015), https://doi.org/10.2147/IJN.S84351.

[132] X.C. Chen, Y.L. Deng, Y. Lin, D.W. Pang, H. Qing, F. Qu, H.Y. Xie, Quantum dot-labeled aptamer nanoprobes specifically targeting glioma cells, Nanotechnology 19 (2008) 235105, https://doi.org/10.1088/0957-4484/19/23/235105.

[133] L. Kunfeng, D. Jiali, J. Hongwei, Y. Xianto, F. Xinmeng, L. Liyu, Z. Yi, G. Zhu, W. Yun, Z. Lihe, Y. Zhenjun, Chemical modification improves stability of DNA aptamer GBI-10 and its 1 affinity towards Tenascin-C, Org. Biomol. Chem. 14 (2016) 1–12, https://doi.org/10.1039/C5OB01898F.

[134] Q. Guo, X. He, C. Li, Y. He, Y. Peng, Yu Zhang, Y. Lu, X. Chen, Y. Zhang, Q. Chen, T. Sun, C. Jiang, Dandelion-like tailorable nanoparticles for tumor microenvironment modulation, Adv. Sci. 6 (2019) 1901430, https://doi.org/10.1002/adv.201901430.

[135] X. He, X. Chen, L. Liu, Yu Zhang, Y. Lu, Yujie Zhang, Q. Chen, C. Ruan, Q. Guo, C. Li, T. Sun, C. Jiang, Sequentially triggered nanoparticles with tumor penetration and intelligent drug release for pancreatic cancer therapy, Adv. Sci. 5 (2018) 1701070, https://doi.org/10.1002/adv.201701070.
[136] K.S. Schmidt, Application of locked nucleic acids to improve aptamer *in vivo* stability and targeting function, Nucleic Acids. Res. 32 (2004) 5757–5765, https://doi.org/10.1093/nar/gkh862.

[137] H.Y. Ko, K.J. Choi, C.H. Lee, S. Kim, A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin αvβ3 and tenascin-C proteins, Biomaterials 32 (2011) 1130–1138, https://doi.org/10.1016/j.biomaterials.2010.10.226.

[138] O. Jacobson, X. Yan, G. Niu, I.D. Weiss, Y. Ma, L.P. Szajek, B. Shen, D. O. Kiesewetter, X. Chen, PET imaging of tenascin-c with a radiolabeled single-stranded DNA aptamer, J. Nucl. Med. 56 (2015) 616–621, https://doi.org/10.2967/jnumed.114.149484.

[139] K. Rolle, S. Nowak, E. Wyszko, M. Zukiel, S. Zukiel, R. Piestreniewicz, I. Gawron ska, M.Z. Barciszewska, J. Barciszewski, Promising human brain tumors therapy with interference RNA intervention (iRNAi), Cancer Biol. Ther. 9 (2010) 397–407, https://doi.org/10.4161/cbt.9.5.10958.

[140] R. Zukiel, S. Nowak, Suppression of human brain tumor with interference RNA specific for tenascin-C, Cancer Biol. Ther. 5 (2006) 1002–1007, https://doi.org/10.4161/cbt.5.8.2886.

[141] T. Murakami, H. Kikuchi, H. Ishimatsu, I. Iino, A. Hirotsu, T. Matsumoto, Y. Ozaki, T. Kawabata, Y. Hiramatsu, M. Ohta, K. Kamiya, M. Fukushima, S. Baba, K. Kitagawa, M. Kitagawa, H. Konno, Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis, Br. J. Cancer 117 (2017) 1360–1370, https://doi.org/10.1038/bjc.2017.291.

[142] S.F. Tavazoie, C. Alarcón, T. Oskarsson, D. Padua, Q. Wang, P.D. Bos, W.L. Gerald, J. Massagué, Endogenous human microRNAs that suppress breast cancer metastasis, Nature 451 (2008) 147–152, https://doi.org/10.1038/nature06487.

[143] K. Koshizuka, N. Nohata, T. Hanazawa, N. Kikkawa, T. Arai, A. Okato, I. Fukumoto, K. Katada, Y. Okamoto, N. Seki, Deep sequencing-based microRNA expression signatures in head and neck squamous cell carcinoma: dual strands of pre-miR-150 as antitumor miRNAs, Oncotarget. 8 (2017) 30288–30304, https://doi.org/10.18632/oncotarget.16327.

[144] M. Saxena, M. Hisano, M. Neutzner, M. Diepenbruck, R. Ivenak, K. Sharma, R.K. R. Kalathur, T.R. Bürglin, S. Risoli, G. Christofori, The long non-coding RNA ET-20 mediates EMT by impairing desmosomes in breast cancer cells, J. Cell Sci. 134 (2021) jcs258418, https://doi.org/10.1242/jcs.258418.

[145] B. Chen, Z. Wang, J. Sun, Q. Song, B. He, H. Zhang, X. Wang, W. Dai, Q. Zhang, A tenascin C targeted nanoliposome with navitoclax for specifically eradicating of cancer-associated fibroblasts, Nanomed. Nanotechnol. Biol. Med. 12 (2016) 131–141, https://doi.org/10.1016/j.nano.2015.10.001.

[146] E. Van Obberghen-Schilling, R.P. Tucker, F. Saupe, I. Gasser, B. Cseh, G. Orend, Fibronectin and tenascin-C: acappositions in fibromatosis during development and tumor growth, Int. J. Dev. Biol. 55 (2011) 511–525, https://doi.org/10.1387/ijdb.1032430e.

[147] R. Chiquet-Ehrismann, P. Kalla, C.A. Pearson, K. Beck, M. Chiquet, Tenascin interferes with fibronectin action, Cell 53 (1988) 383–390, https://doi.org/10.1016/0092-8674(88)90158-4.

[148] L. De Laporte, J.J. Rice, F. Tortelli, J.A. Hubbell, Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain, PLoS. One 8 (2013) e62076, https://doi.org/10.1371/journal.pone.0062076.

[149] M.M. Martino, S.P. Briquez, E. Güç, F. Tortelli, W.W. Kilarski, S. Metzger, J. J. Rice, G.A. Kuhn, R. Müller, M.A. Swartz, J.A. Hubbell, Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing, Science (1979) 343 (2014) 885–888, https://doi.org/10.1126/science.1247663.

[150] D.W. Hwang, H.Y. Ko, J.H. Lee, H. Kang, S.H. Ryu, I.C. Song, D.S. Lee, S. Kim, A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer, J. Nucl. Med. 51 (2010) 98–105, https://doi.org/10.2967/jnumed.109.069880.

[151] J. Lee, G. Stovall, A. Ellington, Aptamer therapeutics advance, Curr. Opin. Chem. Biol. 10 (2006) 282–289, https://doi.org/10.1016/j.cbpa.2006.03.015.

[152] S.E. Osborne, I. Matsumura, A.D. Ellington, Aptamers as therapeutic and diagnostic reagents: problems and prospects, Curr. Opin. Chem. Biol. 1 (1997) 5–9, https://doi.org/10.1016/s1367-5931(97)80102-0.

[153] B.J. Hicke, C. Marion, Y.F. Chang, T. Gould, C.K. Lynott, D. Parma, P.G. Schmidt, S. Warren, Tenascin-C aptamers are generated using tumor cells and purified protein, J. Biol. Chem. 276 (2001) 48644–48654, https://doi.org/10.1074/jbc.M104651200.

[154] B.J. Hicke, A.W. Stephens, T. Gould, Y.F. Chang, C.K. Lynott, J. Heil, S. Borkowski, C.S. Hilger, G. Cook, S. Warren, P.G. Schmidt, Tumor targeting by an aptamer, J. Nucl. Med. 47 (2006) 668–678.

[155] Ko, M.H., Kim, S., Kang, W.J., Lee, J.H., Kang, H., Moon, S.H., Hwang, D.W., Ko, H.Y., Lee, D.S., 2009, *In vitro* derby imaging of cancer biomarkers using quantum dots. Small 5 (2009) 1207–1212. 10.1002/smll.200801580.

[156] W.J. Kang, J.R. Chae, Y.L. Cho, J.D. Lee, S. Kim, Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers, Small. 5 (2009) 2519–2522, https://doi.org/10.1002/smll.200900848.

[157] N.M. Wolters, J.P. MacKeigan, From sequence to function: using RNAi to elucidate mechanisms of human disease, Cell Death. Differ. 15 (2008) 809–819, https://doi.org/10.1038/sj.cdd.4402311.

[158] S. Dang, R. Zhang, S. Tian, P. Hou, G. Li, M. Ji, MicroRNA-218 inhibits the malignant phenotypes of glioma by modulating the TNC/AKT/AP-1/TGFβ1 feedback signaling loop, Int. J. Mol. Med. 48 (2021) 205, https://doi.org/10.3892/jimn.2021.5038.

[159] M.D. Diem, L. Hyun, F. Yi, R. Hippensteel, E. Kuhar, C. Lowenstein, E.J. Swift, K. T. O'Neil, S.A. Jacobs, Selection of high-affinity Centyrin FN3 domains from a

simple library diversified at a combination of strand and loop positions, Protein Eng. Des. Sel. 27 (2014) 419–429, https://doi.org/10.1093/protein/gzu016.

[160] S.A. Jacobs, M.D. Diem, J. Luo, A. Teplyakov, G. Obmolova, T. Malia, G. L. Gilliland, K.T. O'Neil, Design of novel FN3 domains with high stability by a consensus sequence approach, Protein Eng. Des. Sel. 25 (2012) 107–117, https://doi.org/10.1093/protein/gzr064.

[161] D. Klein, S. Goldberg, C.S. Theile, R. Dambra, K. Haskell, E. Kuhar, T. Lin, R. Parmar, M. Manoharan, M. Richter, M. Wu, J. Mendrola Zarazowski, V. Jadhav, M.A. Maier, L. Sepp-Lorenzino, K. O'Neil, V. Dudkin, Centyrin ligands for extrathecal delivery of siRNA, Mol. Ther. 29 (2021) 2053–2066, https://doi.org/10.1016/j.ymthe.2021.02.015.

[162] A. Montinaro, H. Walczak, Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries, Cell Death. Differ. 30 (2023) 237–249, https://doi.org/10.1038/s41418-022-01059-z.

[163] A. Rossin, G. Miloro, A.O. Hueber, TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity, Cancers. (Basel) 11 (2019) 639, https://doi.org/10.3390/cancers11050639.

[164] T. Herrmann, L. Große-Hovest, T. Otz, P.H. Krammer, H.G. Rammensee, G. Jung, Construction of optimized bispecific antibodies for selective activation of the death receptor CD95, Cancer Res. 68 (2008) 1221–1227, https://doi.org/10.1158/0008-5472.CAN-07-6175.

[165] D. Berg, M. Lehne, N. Müller, D. Siegmund, S. Münckler, W. Sebold, K. Pfizenmaier, H. Wajant, Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L, Cell Death. Differ. 14 (2007) 2021–2034, https://doi.org/10.1038/s.cdd.4402213.

[166] H. Okada, L.H. Butterfield, R.L. Hamilton, A. Hoji, M. Sakaki, B.J. Ahn, G. Kohanbash, J. Drappatz, J. Engh, N. Amankulor, M.O. Chan, M. A. Salazar, E.G. Shaw, D.M. Potter, F.S. Lieberman, Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC, Clin. Cancer Res. 21 (2015) 286–294, https://doi.org/10.1158/1078-0432.CCR-14-1790.

[167] H. Okada, P. Kalinski, R. Ueda, A. Hoji, G. Kohanbash, T.E. Donegan, A.H. Mintz, J.A. Engh, D.L. Bartlett, C.K. Brown, H. Zeh, M.P. Holtzman, T.A. Reinhart, T. L. Whiteside, L.H. Butterfield, R.L. Hamilton, D.M. Potter, I.F. Pollack, A. M. Salazar, F.S. Lieberman, Induction of CD8<sup>+</sup> T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma, J. Clin. Oncol. 29 (2011) 330–336, https://doi.org/10.1200/JCO.2010.30.7744.

[168] I.F. Pollack, R.I. Jakacki, L.H. Butterfield, R.L. Hamilton, A. Panigrahy, D. P. Normolle, A.K. Connelly, S. Dibridge, G. Mason, T.L. Whiteside, H. Okada, Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas, Neuro-Oncol 18 (2016) 1157–1168, https://doi.org/10.1093/neuonc/now026.

[169] V. Dutoit, C. Herold-Mende, N. Hilf, O. Schoor, P. Beckhove, J. Bucher, K. Dorsch, S. Flohr, J. Fritsche, P. Lewandrowski, J. Lohr, H.G. Rammensee, S. Stevanovic, C. Trautwein, V. Vass, S. Walter, P.R. Walker, T. Weinschenk, H. Singh-Jasuja, P. Y. Dietrich, Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy, Brain 135 (2012) 1042–1054, https://doi.org/10.1093/brain/awc042.

[170] R. Rampling, S. Peoples, P.J. Mulholland, A. James, O. Al-Salihi, C.J. Twelves, C. McBain, S. Jefferies, A. Jackson, W. Stewart, J. Lindner, S. Kutscher, N. Hilf, L. McGuigan, J. Peters, K. Hill, O. Schoor, H. Singh-Jasuja, S.E. Halford, J.W. A. Ritchie, A cancer research UK first time in human phase I trial of IMA950 (Novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma, Clin. Cancer Res. 22 (2016) 4776–4785, https://doi.org/10.1158/1078-0432.CCR-16-0506.

[171] D. Migliorini, V. Dutoit, M. Allard, N. Grandjean Hallez, E. Marinari, V. Widmer, G. Philippin, F. Corlazzoli, R. Gustave, M. Kreutzfeldt, N. Blazek, J. Wasem, A. Hottinger, A. Koka, S. Momjian, A. Lobrinus, D. Merkler, M.I. Vargas, P. R. Walker, A. Patrikidou, P.Y. Dietrich, Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients, Neuro-Oncol 21 (2019) 923–933, https://doi.org/10.1093/neuonc/noz040.

[172] E. Boydell, E. Marinari, D. Migliorini, P.Y. Dietrich, A. Patrikidou, V. Dutoit, Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients, Cancers. (Basel) 11 (2019) 464, https://doi.org/10.3390/cancers1104046.

[173] R.S. de Oliveira Filho, D.A. De Oliveira, M.M. Nisimoto, L.C. Marti, A review of advanced cutaneous melanoma therapies and their mechanisms, from immunotherapies to lysine histone methyl transferase inhibitors, Cancers. (Basel) 15 (2023) 5751, https://doi.org/10.3390/cancers15245751.

[174] M.J. Lin, J. Svensson-Arvelund, G.S. Lubitz, A. Marabelle, I. Melero, B.D. Brown, J.D. Brody, Cancer vaccines: the next immunotherapy frontier, Nat. Cancer 3 (2022) 911–926, https://doi.org/10.1038/s43018-022-00418-6.

[175] M. Sioud, Releasing the immune system brakes using siRNAs enhances cancer immunotherapy, Cancers. (Basel) 11 (2019) 176, https://doi.org/10.3390/cancers11020176.

[176] A. Mock, R. Warta, C. Geisenberger, R. Bischoff, A. Schulte, K. Lamszus, V. Stadler, T. Felgenhauer, C. Schichor, C. Schwartz, J. Matschke, C. Jungk, R. Ahmadi, F. Sahm, D. Capper, R. Glass, J.C. Tonn, M. Westphal, A. Von Deimling, A. Unterberg, J.L. Bermejo, C. Herold-Mende, Printed peptide arrays identify prognostic TNC serumantibodies in glioma patients, Oncotarget. 6 (2015) 13579–13590, https://doi.org/10.18632/oncotarget.3791.

[177] J. Song, A. Schwenzer, A. Wong, S. Turcinov, C. Rims, L.R. Martinez, D. Arribas-Layton, C. Gerstner, V.S. Muir, K.S. Midwood, V. Malmström, E.A. James, J.
[136] K.S. Schmidt, Application of locked nucleic acids to improve aptamer *in vivo* stability and targeting function, Nucleic Acids. Res. 32 (2004) 5757–5765, https://doi.org/10.1093/nar/gkh862.

[137] H.Y. Ko, K.J. Choi, C.H. Lee, S. Kim, A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin αvβ3 and tenascin-C proteins, Biomaterials 32 (2011) 1130–1138, https://doi.org/10.1016/j.biomaterials.2010.10.226.

[138] O. Jacobson, X. Yan, G. Niu, I.D. Weiss, Y. Ma, L.P. Szajek, B. Shen, D. O. Kiesewetter, X. Chen, PET imaging of tenascin-c with a radiolabeled single-stranded DNA aptamer, J. Nucl. Med. 56 (2015) 616–621, https://doi.org/10.2967/jnumed.114.149484.

[139] K. Rolle, S. Nowak, E. Wyszko, M. Zukiel, S. Zukiel, R. Piestreniewicz, I. Gawron ska, M.Z. Barciszewska, J. Barciszewski, Promising human brain tumors therapy with interference RNA intervention (iRNAi), Cancer Biol. Ther. 9 (2010) 397–407, https://doi.org/10.4161/cbt.9.5.10958.

[140] R. Zukiel, S. Nowak, Suppression of human brain tumor with interference RNA specific for tenascin-C, Cancer Biol. Ther. 5 (2006) 1002–1007, https://doi.org/10.4161/cbt.5.8.2886.

[141] T. Murakami, H. Kikuchi, H. Ishimatsu, I. Iino, A. Hirotsu, T. Matsumoto, Y. Ozaki, T. Kawabata, Y. Hiramatsu, M. Ohta, K. Kamiya, M. Fukushima, S. Baba, K. Kitagawa, M. Kitagawa, H. Konno, Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis, Br. J. Cancer 117 (2017) 1360–1370, https://doi.org/10.1038/bjc.2017.291.

[142] S.F. Tavazoie, C. Alarcón, T. Oskarsson, D. Padua, Q. Wang, P.D. Bos, W.L. Gerald, J. Massagué, Endogenous human microRNAs that suppress breast cancer metastasis, Nature 451 (2008) 147–152, https://doi.org/10.1038/nature06487.

[143] K. Koshizuka, N. Nohata, T. Hanazawa, N. Kikkawa, T. Arai, A. Okato, I. Fukumoto, K. Katada, Y. Okamoto, N. Seki, Deep sequencing-based microRNA expression signatures in head and neck squamous cell carcinoma: dual strands of pre-miR-150 as antitumor miRNAs, Oncotarget. 8 (2017) 30288–30304, https://doi.org/10.18632/oncotarget.16327.

[144] M. Saxena, M. Hisano, M. Neutzner, M. Diepenbruck, R. I vanek, K. Sharma, R.K. R. Kalathur, T.R. Bürglin, S. Risoli, G. Christofori, The long non-coding RNA ET-20 mediates EMT by impairing desmosomes in breast cancer cells, J. Cell Sci. 134 (2021) jcs258418, https://doi.org/10.1242/jcs.258418.

[145] B. Chen, Z. Wang, J. Sun, Q. Song, B. He, H. Zhang, X. Wang, W. Dai, Q. Zhang, A tenascin C targeted nanoliposome with navitoclax for specifically eradicating of cancer-associated fibroblasts, Nanomed. Nanotechnol. Biol. Med. 12 (2016) 131–141, https://doi.org/10.1016/j.nano.2015.10.001.

[146] E. Van Obberghen-Schilling, R.P. Tucker, F. Saupe, I. Gasser, B. Cseh, G. Orend, Fibronectin and tenascin-C: acappositions in fibromatosis during development and tumor growth, Int. J. Dev. Biol. 55 (2011) 511–525, https://doi.org/10.1387/ijdb.103243eo.

[147] R. Chiquet-Ehrismann, P. Kalla, C.A. Pearson, K. Beck, M. Chiquet, Tenascin interferes with fibronectin action, Cell 53 (1988) 383–390, https://doi.org/10.1016/0092-8674(88)90158-4.

[148] L. De Laporte, J.J. Rice, F. Tortelli, J.A. Hubbell, Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain, PLoS. One 8 (2013) e62076, https://doi.org/10.1371/journal.pone.0062076.

[149] M.M. Martino, S.P. Briquez, E. Güç, F. Tortelli, W.W. Kilarski, S. Metzger, J. J. Rice, G.A. Kuhn, R. Müller, M.A. Swartz, J.A. Hubbell, Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing, Science (1979) 343 (2014) 885–888, https://doi.org/10.1126/science.1247663.

[150] D.W. Hwang, H.Y. Ko, J.H. Lee, H. Kang, S.H. Ryu, I.C. Song, D.S. Lee, S. Kim, A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer, J. Nucl. Med. 51 (2010) 98–105, https://doi.org/10.2967/jnumed.109.069880.

[151] J. Lee, G. Stovall, A. Ellington, Aptamer therapeutics advance, Curr. Opin. Chem. Biol. 10 (2006) 282–289, https://doi.org/10.1016/j.cbpa.2006.03.015.

[152] S.E. Osborne, I. Matsumura, A.D. Ellington, Aptamers as therapeutic and diagnostic reagents: problems and prospects, Curr. Opin. Chem. Biol. 1 (1997) 5–9, https://doi.org/10.1016/s1367-5931(97)80102-0.

[153] B.J. Hicke, C. Marion, Y.F. Chang, T. Gould, C.K. Lynnott, D. Parma, P.G. Schmidt, S. Warren, Tenascin-C aptamers are generated using tumor cells and purified protein, J. Biol. Chem. 276 (2001) 48644–48654, https://doi.org/10.1074/jbc.M104651200.

[154] B.J. Hicke, A.W. Stephens, T. Gould, Y.F. Chang, C.K. Lynnott, J. Heil, S. Borkowski, C.S. Hilger, G. Cook, S. Warren, P.G. Schmidt, Tumor targeting by an aptamer, J. Nucl. Med. 47 (2006) 668–678.

[155] Ko, M.H., Kim, S., Kang, W.J., Lee, J.H., Kang, H., Moon, S.H., Hwang, D.W., Ko, H.Y., Lee, D.S., 2009, *In vitro* derby imaging of cancer biomarkers using quantum dots. Small 5 (2009) 1207–1212. 10.1002/smll.200801580.

[156] W.J. Kang, J.R. Chae, Y.L. Cho, J.D. Lee, S. Kim, Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers, Small. 5 (2009) 2519–2522, https://doi.org/10.1002/smll.200900848.

[157] N.M. Wolters, J.P. MacKeigan, From sequence to function: using RNAi to elucidate mechanisms of human disease, Cell Death. Differ. 15 (2008) 809–819, https://doi.org/10.1038/sj.cdd.4402311.

[158] S. Dang, R. Zhang, S. Tian, P. Hou, G. Li, M. Ji, MicroRNA-218 inhibits the malignant phenotypes of glioma by modulating the TNC/AKT/AP-1/TGFβ1 feedback signaling loop, Int. J. Mol. Med. 48 (2021) 205, https://doi.org/10.3892/jimn.2021.5038.

[159] M.D. Diem, L. Hyun, F. Yi, R. Hippensteel, E. Kuhar, C. Lowenstein, E.J. Swift, K. T. O'Neil, S.A. Jacobs, Selection of high-affinity Centyrin FN3 domains from a

simple library diversified at a combination of strand and loop positions, Protein Eng. Des. Sel. 27 (2014) 419–429, https://doi.org/10.1093/protein/gzu016.

[160] S.A. Jacobs, M.D. Diem, J. Luo, A. Teplyakov, G. Obmolova, T. Malia, G. L. Gilliland, K.T. O'Neil, Design of novel FN3 domains with high stability by a consensus sequence approach, Protein Eng. Des. Sel. 25 (2012) 107–117, https://doi.org/10.1093/protein/gzr064.

[161] D. Klein, S. Goldberg, C.S. Theile, R. Dambra, K. Haskell, E. Kuhar, T. Lin, R. Parmar, M. Manoharan, M. Richter, M. Wu, J. Mendrola Zarazowski, V. Jadhav, M.A. Maier, L. Sepp-Lorenzino, K. O'Neil, V. Dudkin, Centyrin ligands for extrathecal delivery of siRNA, Mol. Ther. 29 (2021) 2053–2066, https://doi.org/10.1016/j.ymthe.2021.02.015.

[162] A. Montinaro, H. Walczak, Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries, Cell Death. Differ. 30 (2023) 237–249, https://doi.org/10.1038/s41418-022-01059-z.

[163] A. Rossin, G. Miloro, A.O. Hueber, TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity, Cancers. (Basel) 11 (2019) 639, https://doi.org/10.3390/cancers11050639.

[164] T. Herrmann, L. Große-Hovest, T. Ozt, P.H. Krammer, H.G. Rammensee, G. Jung, Construction of optimized bispecific antibodies for selective activation of the death receptor CD95, Cancer Res. 68 (2008) 1221–1227, https://doi.org/10.1158/0008-5472.CAN-07-6175.

[165] D. Berg, M. Lehne, N. Müller, D. Siegmund, S. Münckler, W. Sebold, K. Pfizenmaier, H. Wajant, Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L, Cell Death. Differ. 14 (2007) 2021–2034, https://doi.org/10.1038/s.cdd.4402213.

[166] H. Okada, L.H. Butterfield, R.L. Hamilton, A. Hoji, M. Sakaki, B.J. Ahn, G. Kohanbash, J. Drappatz, J. Engh, N. Amankulor, M.O. Chan, M. A. Salazar, E.G. Shaw, D.M. Potter, F.S. Lieberman, Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC, Clin. Cancer Res. 21 (2015) 286–294, https://doi.org/10.1158/1078-0432.CCR-14-1790.

[167] H. Okada, P. Kalinski, R. Ueda, A. Hoji, G. Kohanbash, T.E. Donegan, A.H. Mintz, J.A. Engh, D.L. Bartlett, C.K. Brown, H. Zeh, M.P. Holtzman, T.A. Reinhart, T. L. Whiteside, L.H. Butterfield, R.L. Hamilton, D.M. Potter, I.F. Pollack, A. M. Salazar, F.S. Lieberman, Induction of CD8<sup>+</sup> T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma, J. Clin. Oncol. 29 (2011) 330–336, https://doi.org/10.1200/JCO.2010.30.7744.

[168] I.F. Pollack, R.I. Jakacki, L.H. Butterfield, R.L. Hamilton, A. Panigrahy, D. P. Normolle, A.K. Connelly, S. Dibridge, G. Mason, T.L. Whiteside, H. Okada, Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas, Neuro-Oncol 18 (2016) 1157–1168, https://doi.org/10.1093/neuonc/now026.

[169] V. Dutoit, C. Herold-Mende, N. Hilf, O. Schoor, P. Beckhove, J. Bucher, K. Dorsch, S. Flohr, J. Fritsche, P. Lewandrowski, J. Lohr, H.G. Rammensee, S. Stevanovic, C. Trautwein, V. Vass, S. Walter, P.R. Walker, T. Weinschenk, H. Singh-Jasuja, P. Y. Dietrich, Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy, Brain 135 (2012) 1042–1054, https://doi.org/10.1093/brain/awc042.

[170] R. Rampling, S. Peoples, P.J. Mulholland, A. James, O. Al-Salihi, C.J. Twelves, C. McBain, S. Jefferies, A. Jackson, W. Stewart, J. Lindner, S. Kutscher, N. Hilf, L. McGuigan, J. Peters, K. Hill, O. Schoor, H. Singh-Jasuja, S.E. Halford, J.W. A. Ritchie, A cancer research UK first time in human phase I trial of IMA950 (Novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma, Clin. Cancer Res. 22 (2016) 4776–4785, https://doi.org/10.1158/1078-0432.CCR-16-0506.

[171] D. Migliorini, V. Dutoit, M. Allard, N. Grandjean Hallez, E. Marinari, V. Widmer, G. Philippin, F. Corlazzoli, R. Gustave, M. Kreutzfeldt, N. Blazek, J. Wasem, A. Hottinger, A. Koka, S. Momjian, A. Lobrinus, D. Merkler, M.I. Vargas, P. R. Walker, A. Patrikidou, P.Y. Dietrich, Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients, Neuro-Oncol 21 (2019) 923–933, https://doi.org/10.1093/neuonc/noz040.

[172] E. Boydell, E. Marinari, D. Migliorini, P.Y. Dietrich, A. Patrikidou, V. Dutoit, Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients, Cancers. (Basel) 11 (2019) 464, https://doi.org/10.3390/cancers1104046.

[173] R.S. de Oliveira Filho, D.A. De Oliveira, M.M. Nisimoto, L.C. Marti, A review of advanced cutaneous melanoma therapies and their mechanisms, from immunotherapies to lysine histone methyl transferase inhibitors, Cancers. (Basel) 15 (2023) 5751, https://doi.org/10.3390/cancers15245751.

[174] M.J. Lin, J. Svensson-Arvelund, G.S. Lubitz, A. Marabelle, I. Melero, B.D. Brown, J.D. Brody, Cancer vaccines: the next immunotherapy frontier, Nat. Cancer 3 (2022) 911–926, https://doi.org/10.1038/s43018-022-00418-6.

[175] M. Sioud, Releasing the immune system brakes using siRNAs enhances cancer immunotherapy, Cancers. (Basel) 11 (2019) 176, https://doi.org/10.3390/cancers11020176.

[176] A. Mock, R. Warta, C. Geisenberger, R. Bischoff, A. Schulte, K. Lamszus, V. Stadler, T. Felgenhauer, C. Schichor, C. Schwartz, J. Matschke, C. Jungk, R. Ahmadi, F. Sahm, D. Capper, R. Glass, J.C. Tonn, M. Westphal, A. Von Deimling, A. Unterberg, J.L. Bermejo, C. Herold-Mende, Printed peptide arrays identify prognostic TNC serumantibodies in glioma patients, Oncotarget. 6 (2015) 13579–13590, https://doi.org/10.18632/oncotarget.3791.

[177] J. Song, A. Schwenzer, A. Wong, S. Turcinov, C. Rims, L.R. Martinez, D. Arribas-Layton, C. Gerstner, V.S. Muir, K.S. Midwood, V. Malmström, E.A. James, J.
H. Buckner, Shared recognition of citrullinated tenascin-C peptides by T and B cells in rheumatoid arthritis, JCI. Insight. 6 (2021) e145217, https://doi.org/10.1172/jci.insight.145217.

[178] R.O. Hynes, The extracellular matrix: not just pretty fibrils, Science 326 (2009) 1216–1219, https://doi.org/10.1126/science.1176009.

[179] A. Naik, A. Leask, Tumor-associated fibrosis impairs the response to immunotherapy, Matrix Biol. 119 (2023) 125–140, https://doi.org/10.1016/j.matbio.2023.04.002.

[180] R.O. Hynes, A. Naba, Overview of the matrisome—an inventory of extracellular matrix constituents and functions, Cold Spring Harb. Perspect. Biol. 4 (2012) a004903, https://doi.org/10.1101/cshperspect.a004903.

[181] L. Albacete-Albacete, I. Navarro-Lérida, J.A. López, I. Martín-Padura, A. M. Astudillo, A. Ferrarini, M. Van-Der-Heyden, J. Balsinde, G. Orend, J. Vázquez, M.Á. Del Pozo, ECM deposition is driven by caveolin-1-dependent regulation of exosomal biogenesis and cargo sorting, J. Cell Biol. 219 (2020) e202006178, https://doi.org/10.1083/jcb.202006178.

[182] K.S. Midwood, G. Orend, The role of tenascin-C in tissue injury and tumorigenesis, J. Cell Commun. Signal. 3 (2009) 287–310, https://doi.org/10.1007/s12079-009-0075-1.

[183] F. Saupe, A. Schwenzer, Y. Jia, I. Gasser, C. Spenlé, B. Langlois, M. Kammerer, O. Lefebvre, R. Hlushchuk, T. Rupp, M. Marko, M. van der Heyden, G. Cremel, C. Arnold, A. Klein, P. Simon-Assmann, V. Djonov, A. Neuville-Méchine, I. Esposito, J. Slotta-Huspenina, K.P. Janssen, O. de Wever, G. Christofori, T. Hussenet, G. Orend, Tenascin-C downregulates Wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model, Cell Rep. 5 (2013) 482–492, https://doi.org/10.1016/j.celrep.2013.09.014.

[184] E. Henke, R. Nandigama, S. Ergün, Extracellular matrix in the tumor microenvironment and its impact on cancer therapy, Front. Mol. Biosci. 6 (2020) 160, https://doi.org/10.3389/fmolb.2019.00160.

[185] K. Khalaf, D. Hana, J.T.T. Chou, C. Singh, A. Mackiewicz, M. Kaczmarek, Aspects of the tumor microenvironment involved in immune resistance and drug

resistance, Front. Immunol. 12 (2021) 656364, https://doi.org/10.3389/fimmu.2021.656364.

[186] A.M. Monjazeb, K.A. Schalper, F. Villarroel-Espindola, A. Nguyen, S.L. Shiao, K. Young, Effects of radiation on the tumor microenvironment, Semin. Radiat. Oncol. 30 (2020) 145–157, https://doi.org/10.1016/j.semradonc.2019.12.004.

[187] J. Alexandre, J. Cautela, S. Ederhy, G.L. Damaj, J. Salem, F. Barlesi, L. Farnault, A. Charbonnier, M. Mirabel, S. Champiat, A. Cohen-Solal, A. Cohen, C. Dolladille, F. Thuny, Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines, J. Am. Heart Assoc. 9 (2020) e018403, https://doi.org/10.1161/JAHA.120.018403.

[188] A. Choksey, K.N. Timm, Cancer therapy-induced cardiotoxicity—a metabolic perspective on pathogenesis, diagnosis and therapy, Int. J. Mol. Sci. 23 (2021) 441, https://doi.org/10.3390/ijms23010441.

[189] M.H. Joyce, C. Lu, E.R. James, R. Hegab, S.C. Allen, L.J. Suggs, A. Brock, Phenotypic basis for matrix stiffness-dependent chemoresistance of breast cancer cells to doxorubicin, Front. Oncol. 8 (2018) 337, https://doi.org/10.3389/fonc.2018.00337.

[190] R. Liang, G. Song, Matrix stiffness-driven cancer progression and the targeted therapeutic strategy, Mechanobiol. Med. 1 (2023) 100013, https://doi.org/10.1016/j.mbm.2023.100013.

[191] N. Albinger, J. Hartmann, E. Ullrich, Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany, Gene Ther. 28 (2021) 513–527, https://doi.org/10.1038/s41434-021-00246-w.

[192] C. Martín-Otal, A. Lasarte-Cia, D. Serrano, N. Casares, E. Conde, F. Navarro, I. Sánchez-Moreno, M. Gorraíz, P. Sarrión, A. Calvo, C.E. De Andrea, J. Echeveste, A. Vilas, J.R. Rodriguez-Madoz, J. San Miguel, F. Prosper, S. Hervas-Stubbs, J. J. Lasarte, T. Lozano, Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells, J. Immunother. Cancer 10 (2022) e004479, https://doi.org/10.1136/jitc-2021-004479.
H. Buckner, Shared recognition of citrullinated tenascin-C peptides by T and B cells in rheumatoid arthritis, JCI. Insight. 6 (2021) e145217, https://doi.org/10.1172/jci.insight.145217.

[178] R.O. Hynes, The extracellular matrix: not just pretty fibrils, Science 326 (2009) 1216–1219, https://doi.org/10.1126/science.1176009.

[179] A. Naik, A. Leask, Tumor-associated fibrosis impairs the response to immunotherapy, Matrix Biol. 119 (2023) 125–140, https://doi.org/10.1016/j.matbio.2023.04.002.

[180] R.O. Hynes, A. Naba, Overview of the matrisome—an inventory of extracellular matrix constituents and functions, Cold Spring Harb. Perspect. Biol. 4 (2012) a004903, https://doi.org/10.1101/cshperspect.a004903.

[181] L. Albacete-Albacete, I. Navarro-Lérida, J.A. López, I. Martín-Padura, A. M. Astudillo, A. Ferrarini, M. Van-Der-Heyden, J. Balsinde, G. Orend, J. Vázquez, M.Á. Del Pozo, ECM deposition is driven by caveolin-1-dependent regulation of exosomal biogenesis and cargo sorting, J. Cell Biol. 219 (2020) e202006178, https://doi.org/10.1083/jcb.202006178.

[182] K.S. Midwood, G. Orend, The role of tenascin-C in tissue injury and tumorigenesis, J. Cell Commun. Signal. 3 (2009) 287–310, https://doi.org/10.1007/s12079-009-0075-1.

[183] F. Saupe, A. Schwenzer, Y. Jia, I. Gasser, C. Spenlé, B. Langlois, M. Kammerer, O. Lefebvre, R. Hlushchuk, T. Rupp, M. Marko, M. van der Heyden, G. Cremel, C. Arnold, A. Klein, P. Simon-Assmann, V. Djonov, A. Neuville-Méchine, I. Esposito, J. Slotta-Huspenina, K.P. Janssen, O. de Wever, G. Christofori, T. Hussenet, G. Orend, Tenascin-C downregulates Wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model, Cell Rep. 5 (2013) 482–492, https://doi.org/10.1016/j.celrep.2013.09.014.

[184] E. Henke, R. Nandigama, S. Ergün, Extracellular matrix in the tumor microenvironment and its impact on cancer therapy, Front. Mol. Biosci. 6 (2020) 160, https://doi.org/10.3389/fmolb.2019.00160.

[185] K. Khalaf, D. Hana, J.T.T. Chou, C. Singh, A. Mackiewicz, M. Kaczmarek, Aspects of the tumor microenvironment involved in immune resistance and drug

resistance, Front. Immunol. 12 (2021) 656364, https://doi.org/10.3389/fimmu.2021.656364.

[186] A.M. Monjazeb, K.A. Schalper, F. Villarroel-Espindola, A. Nguyen, S.L. Shiao, K. Young, Effects of radiation on the tumor microenvironment, Semin. Radiat. Oncol. 30 (2020) 145–157, https://doi.org/10.1016/j semradonc.2019.12.004.

[187] J. Alexandre, J. Cautela, S. Ederhy, G.L. Damaj, J. Salem, F. Barlesi, L. Farnault, A. Charbonnier, M. Mirabel, S. Champiat, A. Cohen-Solal, A. Cohen, C. Dolladille, F. Thuny, Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines, J. Am. Heart Assoc. 9 (2020) e018403, https://doi.org/10.1161/JAHA.120.018403.

[188] A. Choksey, K.N. Timm, Cancer therapy-induced cardiotoxicity—a metabolic perspective on pathogenesis, diagnosis and therapy, Int. J. Mol. Sci. 23 (2021) 441, https://doi.org/10.3390/ijms23010441.

[189] M.H. Joyce, C. Lu, E.R. James, R. Hegab, S.C. Allen, L.J. Suggs, A. Brock, Phenotypic basis for matrix stiffness-dependent chemoresistance of breast cancer cells to doxorubicin, Front. Oncol. 8 (2018) 337, https://doi.org/10.3389/fonc.2018.00337.

[190] R. Liang, G. Song, Matrix stiffness-driven cancer progression and the targeted therapeutic strategy, Mechanobiol. Med. 1 (2023) 100013, https://doi.org/10.1016/j.mbm.2023.100013.

[191] N. Albinger, J. Hartmann, E. Ullrich, Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany, Gene Ther. 28 (2021) 513–527, https://doi.org/10.1038/s41434-021-00246-w.

[192] C. Martín-Otal, A. Lasarte-Cia, D. Serrano, N. Casares, E. Conde, F. Navarro, I. Sánchez-Moreno, M. Gorraíz, P. Sarrión, A. Calvo, C.E. De Andrea, J. Echeveste, A. Vilas, J.R. Rodriguez-Madoz, J. San Miguel, F. Prosper, S. Hervas-Stubbs, J. J. Lasarte, T. Lozano, Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells, J. Immunother. Cancer 10 (2022) e004479, https://doi.org/10.1136/jitc-2021-004479.